Integrated technology platform for accelerated discovery of antiviral antibody therapeutics

AUTHORS: Pavlo Gilchuk^{1*}, Robin G. Bombardi^{1*}, Jesse H. Erasmus^{3*}, Qing Tan^{9*}, Rachel Nargi^{1*}, Cinque Soto^{1*}, Peter Abbink^{6*,} Todd J Suscovich^{7*}, Lorellin A. Durnell⁹, Amit Khandhar³, Jacob Archer³, Jenny Liang⁸, Mallorie E. Fouch⁸, Edgar Davidson⁸, Benjamin J. Doranz⁸, Taylor Jones¹, Elise Larson³, Stacey Ertel³, Brian Granger³, Jasmine Fuerte-Stone³, Vicky Roy⁷, Thomas Broge⁷, Thomas C. Linnekin⁷, Caitlyn H. Linde⁷, Matthew J. Gorman⁷, Joseph Nkolola⁶, Galit Alter⁷, Steven G. Reed³, Dan H. Barouch^{6,7}, Michael S. Diamond^{9,10,11,12}, James E. Crowe, Jr.^{1,2,4,5}, Neal Van Hoeven^{3**}, Larissa Thackray^{9**}, Robert Carnahan^{1,5**}

Affiliations:

¹Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. ²Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.

³Pre-Clinical Vaccine Development, Infectious Disease Research Institute, Seattle, WA, 98102, USA.

⁴Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, 37232, USA

⁵Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.

⁶Center for Virology and Vaccine Research. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.

⁷Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.12.090944; this version posted May 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

⁸Integral Molecular, Inc., Philadelphia, PA 19104

⁹Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

¹⁰Department of Molecular Microbiology, Washington University School of Medicine, St. Louis,

MO, USA

¹¹Department of Pathology & Immunology, Washington University School of Medicine, St. Louis,

MO, USA

¹²Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs,

Washington University School of Medicine, St. Louis, MO, USA

Contact information:

Robert Carnahan, Ph.D. [LEAD CONTACT]

Department of Pediatrics and the Vanderbilt Vaccine Center

Mail:

Vanderbilt Vaccine Center

11475 Medical Research Building IV

2213 Garland Avenue

Nashville, TN 37232-0417, USA

Telephone (615) 343-8064

Email robert.carnahan@vumc.org

Additional Title Page Footnotes

^{*} These authors contributed equally

**Corresponding author.

Abstract

The emergence and reemergence of highly virulent viral pathogens with pandemic potential has created an urgent need for accelerated discovery of antiviral therapeutics. Antiviral human monoclonal (mAbs) are promising drug candidates to prevent or treat severe viral diseases, but the long timelines needed for discovery limits their rapid deployment and use. Here, we report the development of an integrated sequence of technologies incorporating advances in single-cell mRNA sequence analysis, bioinformatics, synthetic biology, and high-throughput functional analysis that allowed us to discover highly potent antiviral human mAbs and validate their activity *in vivo* at an unprecedented scale, speed, and efficiency. In a 78-day study, modeling deployment of a rapid response platform to an outbreak, we isolated >100 individual Zika virus (ZIKV) specific human mAbs, assessed their function, identified 29 broadly-neutralizing mAbs, and verified therapeutic potency of lead candidates with antibody-encoding mRNA formulation and/or IgG protein delivery in mice and nonhuman primates. Our work provides a roadmap for the rapid antibody discovery programs against viral pathogens of global concern.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.12.090944; this version posted May 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Main

Human monoclonal antibodies (mAbs) are increasingly being considered as therapeutic countermeasures for viral infectious diseases. In recent years, advances in human B cell isolation and antibody variable gene sequencing techniques have led to the identification of large numbers of therapeutic mAb candidates against many life-threatening viral pathogens. These targets include antigenically variable viruses such as human immunodeficiency virus¹ and influenza virus², newly emerging pathogens with high epidemic potential including Ebola virus³, Marburg virus⁴, Zika virus (ZIKV)⁵⁻⁷, Lassa virus⁸, Middle East respiratory syndrome coronavirus (MERS-CoV)⁹, poxviruses¹⁰, Nipah virus¹¹ and many other medically important viruses. Over 25 antiviral human mAbs are now being evaluated as therapeutics in clinical trials^{12,13}.

Large human epidemics of zoonotic diseases are occurring on a regular basis. For example, Ebola virus reportedly caused 28,646 cases of disease and 11,323 deaths in the 2013–2016 epidemic in West Africa¹⁴, the 2015-2016 ZIKV epidemic resulted in millions of infections in new geographic areas^{15,16} and recently, a novel, highly transmissible coronavirus, 2019-nCoV emerged in China and spread globally such that by February 27th, 2020, 82,294 cases and 2,747 deaths have been reported (WHO: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports). These events highlight the potential of viral infections to cause global health emergencies and the need for rapid response platforms to accelerate development of medical countermeasures. Several obstacles impede progress in widespread application of antiviral mAb therapies in outbreak scenarios. A principal impediment to deployment of human antiviral mAbs is the difficulty in predicting which pathogen will cause an epidemic in the short term, and the long timeline needed for human mAb discovery and verification of therapeutic potency.

The goal of this study was to develop and demonstrate the capability of an integrated platform for accelerated discovery of potent human antiviral mAbs that are suitable for therapeutic development. As a model, we used the reemerging pathogen ZIKV that is now endemic in multiple continents¹⁷ and potentially could be controlled with a neutralizing mAb treatment^{5,16,18,19}. We designed an integrated workflow that could accomplish both discovery and validation of protective efficacy in small animals and nonhuman primates (NHP) in less than 90 days. The objectives were to execute rapidly a sequence of tasks including virus stock production, target-specific antibody genes rescue, bioinformatics analysis, mAb gene synthesis, mAb functional *in vitro* analysis, validation of mAb *in vivo* activity using IgG protein and RNA-encoded mAb delivery in mouse model, and proof-of-principle NHP protection studies, as outlined in **Fig. 1**. The workflow implemented high-throughput and redundant approaches, with the goal of streamlining mAb discovery and building in orthogonal approaches to overcome or mitigate failure of critical experimental processes.

Results

Virus stock production

We used a contemporary ZIKV strain of the Asian lineage (Brazil, Paraiba 2015) and a historical ZIKV strain of the African lineage (Dakar, Senegal 1984) to account for genetic diversity and ultimately breadth of protection. To model ZIKV infection in mice, we also used a mouse-adapted isolate of ZIKV Dakar (ZIKV Dakar MA), which has a single gain-of-function mutation in the viral NS4B protein that overcomes mouse innate immune restriction²⁰. To model production of a high-titer virus stock for an unknown pathogen, we evaluated the growth of ZIKV in a panel of cell lines that are commonly used for virus propagation. High levels of virus replication were observed in Vero, U20S, A549, and Huh7 cell




Fig. 1. Integrated technology workflow for rapid discovery of anti-viral human mAbs.

A cartoon of proposed integrated technology workflow that incorporated pathogen production, target-specific B cell isolation, single-cell VD(J) genes sequence analysis, bioinformatics analysis, mAb production, mAb *in vitro* validation, mAb-encoding RNA synthesis, and mAb *in vivo* validation using protein and nucleic acid delivery technologies. Timeline to identify and validate protective mAbs against ZIKV is indicated in the timeline chart, where day 0 is designated as a start point, and day 90 was the projected endpoint for this study. Green star (day 78) depicts the completion time.

lines, as determined by quantitative reverse-transcription PCR (qRT-PCR) (**Supplementary Fig. 1a**), showing the utility of this approach for rapid identification of a permissive cell line(s). Identifying suitable conditions for large-scale production of the virus for subsequent *in vitro* and *in vivo* studies (**Supplementary Fig. 1b-c**) was accomplished in 21 days. Of note, the virus production was performed simultaneously and in a parallel with initial mAb discovery steps, and therefore, the virus was obtained when it was needed for the neutralizing activity screening step with purified mAbs, as detailed below.

Antibody variable gene sequence analysis and bioinformatic processing


To model a rapid response to a previously known pathogen, we used a mAb discovery approach that assumed the envelope protein (ZIKV E protein) on the virion surface is a key protective antigen^{5,6,21,22}. We used memory B cells from previously infected human subjects as the source for antibody discovery (**Supplementary Table 1**). The frequency of ZIKV E-specific memory B cells in most human subjects with prior ZIKV infection is low^{23} . Therefore, we pooled peripheral blood mononuclear cells (PBMCs) from a cohort of several subjects with previous exposure to ZIKV that were pre-screened for E-specific memory B cell responses (**Supplementary Fig. 2**). B cells were enriched using antibody-coated magnetic beads and stained with phenotyping antibodies and soluble recombinant ZIKV E protein (see *Methods*). Antigen-labeled IgG class-switched memory B cell-E complexes were isolated in bulk using fluorescence activated cell sorting (FACS) (**Fig. 2a**). To optimize the breadth of our mAb panel for diverse epitope specificities, we used several B cell isolation approaches that were based on direct or indirect labeling with ZIKV E protein, which resulted in generation of three independent sub-panels of mAbs (**Supplementary Table 2**). Overall, > 5,000 E-labeled B cells were sorted.

To rescue the paired heavy and light chain antibody variable gene sequences from sorted B cells, we used a commercial single-cell encapsulation automated system (Chromium Technology; 10x Genomics Inc). A feature of this sequencing approach is the unprecedented scale of paired antibody variable gene analysis, which is achieved by encapsulation of single B cells via droplet microfluidics²⁴. Approximately 800 sorted antigen-labeled B cells from the single specimen of pooled human cells were subjected to library preparation and sequencing using the Chromium Controller device immediately after cell isolation by FACS. The remaining sorted cells were bulk-expanded in culture, and then the antibody variable genes for single cells were sequenced using Chromium Technology.

Using bioinformatics sieving, we down-selected the total pool of possible sequences to choose 598 paired antibody heavy and light chain variable gene sequences for further evaluation (**Fig. 2b**). The filtered panel included mAbs of defined IgG isotypes, selecting the most somatically mutated individual clone in each antibody clonotype (*i.e.*, the clone with the most mutations compared to the inferred germline gene segments in the lineage of related sequences). Clonotypes were identified based on the presence of identical inferred germline V and J gene assignments and identical amino acid sequences of the CDR (See *Methods*).

Synthetic cDNA constructs based on the sequences of all 598 selected ZIKV mAb candidates were synthesized using a rapid high-throughput cDNA synthesis platform (Twist Bioscience) and cloned into an IgG1 monocistronic expression vector for mammalian cell culture mAb secretion. This vector contains an enhanced 2A sequence and GSG linker that allows simultaneous expression of mAb heavy and light chain genes from a single construct upon transfection²⁵.

Fig. 2. Rescue and sequence analysis of antibody genes from ZIKV E antigen-specific human B cells.



a, Flow cytometric identification of target-specific memory B cells after labeling of magnetically enriched total B cells with ZIKV E antigen. Target-specific B cells were labeled with biotinylated recombinant E protein and detected by fluorochrome-conjugated streptavidin as indicated. Green arrow indicates FACS-sorted cells. Representative data of four experiments is shown.

b, Bioinformatics filtering steps to select mAb sequences for synthesis.


Timeline to identify sequences of target mAbs and obtain cDNA constructs for recombinant mAb expression is indicated with blue arrow in the timeline chart.


In summary, starting from human subject samples, in 17 days we produced recombinant IgG expression vectors for nearly 600 human mAbs from single cells representing independent genetic clonotypes that were ready for expression and functional validation (**Supplementary Table 2**). The data demonstrated capability for rapid target-specific B cell selection and large-scale human antibody discovery, for a setting in which a known protective viral antigen is available.

High-throughput mAb production and functional screening

We adopted high-throughput assays for rapid production, purification, and functional analysis of mAbs from small sample volumes (designated here as "micro-scale") to identify lead mAb candidates for *in vivo* studies. To produce mAbs, we performed transfection of Chinese hamster ovary (CHO) cell cultures using ~1 mL cell culture volume per antibody, and mAbs subsequently were purified using a micro-scale parallel purification approach. Of the 598 mAb cDNAs tested, 475 were produced successfully as recombinant IgG proteins, with a median yield of ~29 μ g of purified antibody from a single 1 mL culture (**Fig. 3a; Supplementary Table 2**).

Antibodies can mediate protection by diverse mechanisms, including direct virus neutralization and/or engagement of innate immune cells via their Fc receptors (FcRs)^{26,27}. Potent neutralization and Fc effector functions are desirable mAb features that can be used to prioritize candidate mAbs for *in vivo* testing. For rapid identification of neutralizing mAbs within the large panel we expressed, we used a real-time cell analysis (RTCA) cellular impedance assay. RTCA assesses kinetic changes in cell physiology, including virus-induced cytopathic effect (CPE), which offers a generic screening approach for mAb neutralizing activity against cytopathic viruses^{28,29}. Our comparative side-by-side study showed that the RTCA performed similarly to a conventional focus-reduction neutralization test (FRNT) to identify neutralizing





a, Micro-scale expressed and purified mAbs. Dots indicate average concentration of individual mAbs from assay duplicates, and median mAb yield is shown with horizontal line. LOD - limit of the detection.

b, Relationships between binding and neutralizing activities of individual mAbs of the panel shown as a heatmap. Binding to E protein was determined by ELISA and neutralizing activity was measured using RTCA from mAbs purified as in (a).

c, ZIKV E protein binding by potently neutralizing mAbs representing three distinct epitope binding groups. MAb rRSV-90, which is specific to the unrelated respiratory syncytial virus (RSV) fusion protein (F) antigen, served as a control.


d, Neutralization of ZIKV Brazil or Dakar strain viruses by representative cross-neutralizing mAbs from (c), as determined using RTCA. Data shown indicate the mean \pm SD of assay triplicates in (c, d), and represent at least two independent experiments. Timeline to identify mAb candidates for *in vivo* testing is indicated with a blue arrow in the timeline chart.

mAbs against ZIKV (**Supplementary Table 2**). However, RTCA offered an advantage for the large mAb panel analysis due to its speed and automation — 24 to 36 hours for the initial qualitative screening of neutralizing activity, and ~48 hours for determination of half maximal inhibitory concentration (IC₅₀) values and ranking of ZIKV mAbs by neutralizing potency (**Supplementary Fig. 3**). Approximately 15% percent (92 of 598) of the mAbs bound strongly to recombinant ZIKV E protein as measured by ELISA, and ~8% (48 of 598) of the mAbs neutralized ZIKV (**Fig. 3b-d; Supplementary Table 2**). Fourteen additional ZIKV-specific mAbs were identified only by neutralization, as they did not show detectable binding to the recombinant E antigen in the solid-phase by ELISA, even though their B cells were sorted with the same antigen in solution. Thus, using a combination of binding and neutralization assays, we validated that at least 106 of the mAbs from the panel were ZIKV-specific (**Supplementary Table 2**).

The subjects we studied likely had been infected with a strain of Asian lineage of ZIKV, since they contracted the disease during the recent outbreak in South America (**Supplementary Table 1**). Twentynine mAbs of the panel possessed neutralizing activity against viruses that were antigenically homologous (Brazil strain; Asian lineage) or heterologous (Dakar strain; African lineage) to the infecting strain (**Supplementary Table 2**). Twenty mAbs fully neutralized at least one of two tested viruses, with estimated IC₅₀ values from RTCA data ranging from about 7 to 1,100 ng/mL, and 15 mAbs fully neutralized both viruses (**Fig. 4**). The three most potent mAbs by neutralization IC₅₀ value (designated mAbs ZIKV-893, -752, and -940) neutralized both Brazil and Dakar ZIKV strains with IC₅₀ values below 100 ng/mL but exhibited differential binding to recombinant E protein. ZIKV-752 bound E strongly, ZIKV-940 bound weakly, and binding of ZIKV-893 was not detected at the highest mAb concentration tested (10 µg/mL) (**Fig. 3c-d; 4**). Competition-binding analysis with the previously characterized ZIKV E-specific human mAbs ZIKV-117 (recognizes the E protein dimer-dimer interface in domain II on viral

Fig. 4. Binding and functional activities of lead human ZIKV mAb therapeutic candidates selected for in vivo testing

mAb clone	ELISA binding to recombinant E (Yes/No)	Epitope specificity	Virus neutralization RTCA IC50 (ng/mL)	
			Dakar	Brazil
ZIKV-423	Y	DIII	>3,000	305
ZIKV-434	—	ND	112	308
ZIKV-518	Y	DIII	>3,000	59
ZIKV-608	Y	DIII	>3,000	118
ZIKV-609	Y	DII*	204	125
ZIKV-624	—	ND	689	190
ZIKV-635	Y	ND	90	171
ZIKV-652	Y	DII	309	192
ZIKV-668	—	ND	128	195
ZIKV-681	Y	DIII	>3,000	420
ZIKV-682	Y	ND	221	204
ZIKV-684	Y	DIII	60	214
ZIKV-752	Y	DIII*	7	12
ZIKV-869	—	DII*	283	215
ZIKV-893	—	DII*	38	58
ZIKV-922	Y	DIII	>3,000	235
ZIKV-940	Y	DI/II*	22	52
ZIKV-980	Y	DIII*	101	45
ZIKV-1006	Y	DII*	128	138
ZIKV-1007	Y	ND	1,100	426
Control (ZIKV-117)	Y	DII	8	7



Twenty mAbs were selected as lead therapeutic candidates on the basis of neutralizing potency and breadth. The measured activities of mAbs are indicated with values and presented as a heatmap. The "*" symbol indicates epitope specificity that was mapped precisely by a shotgun mutagenesis assay assessing loss of binding of point mutant E proteins. Timeline to scale-up mAb protein and mAb-encoding RNA production for in vivo testing in mice is indicated with a blue arrow in the timeline chart.

particles)³⁰, ZIKV-116 (binds to the E protein domain III lateral ridge epitope)³¹, and ZIKV-88 (specific for the E protein fusion loop)⁵, showed that the three newly identified neutralizing mAbs ZIKV-893, -752, and -940 recognized non-overlapping epitopes (**Fig. 4; Supplementary Table 2**). This conclusion was supported by epitope mapping data from loss-of-binding analysis to a ZIKV prM-E protein alanine scanning mutagenesis library expressed in cells⁵. Notably, these mAbs were identified from three different E-antigen sorting strategies (**Supplementary Table 2**). This finding highlighted the importance of study design in the antibody discovery workflow, which relied on concurrent independent strategies for B cell isolation conducted in parallel to identify potently neutralizing mAbs of diverse epitope specificity.

To demonstrate that Fc-mediated function profile could be determined rapidly for this large mAb panel, we performed antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP), and antibody-dependent complement deposition assays in a 384-well format. These assays used immobilized ZIKV E protein and high-throughput flow cytometric analysis to determine the capacity of bound mAb to activate human effector cells *in vitro*. Many mAbs of the panel revealed a high capacity to engage FcRs (**Supplementary Table 2**), showing the utility of the approach for rapid identification of mAbs leveraging Fc function.

In summary, these data demonstrated the high performance of a suite of micro-scale assays in an integrated workflow and accomplished accelerated production and functional analysis of large panels of recombinant human antibodies to identify lead candidates for *in vivo* studies – all of which was accomplished in 13 days.

IgG protein and RNA production for the lead therapeutic mAb candidates for in vivo studies

We selected 20 lead mAb candidates for *in vivo* testing. We administered the mAbs using two different delivery systems: 1) recombinant IgG protein expressed in mammalian cell culture, and 2) mRNA delivery of antibody genes to allow *in vivo* expression of antibodies from transient gene transfer. We initiated production of 20 recombinant IgG proteins in cultures scaled to obtain 3-7 milligrams of purified IgG. In parallel, the same 20 antibody variable gene sequences were cloned into a reading frame for human IgG1 and sub-cloned into plasmids containing an alphavirus replicon³² for *in vivo* study with nucleic acid delivery. To deliver the replicon, we chose a cationic nanostructured lipid carrier (NLC) formulation, in which RNA is bound to the nanoparticle surface by electrostatic association, allowing for rapid formulation³². Linearized DNAs were used as template to transcribe and post-transcriptionally cap replicon RNA at a 500 µg scale. The IgG protein preparation and RNA production and formulation both were accomplished in parallel in eight days.

Protective efficacy of identified neutralizing mAbs in a lethal ZIKV challenge mouse model

We next used an established lethal, immunocompromised challenge model in mice for ZIKV^{5,21} to evaluate the protective capacity of the 20 lead candidate mAbs (**Fig. 4; Supplementary Table 3-4**) and identify lead mAbs for NHP studies. In prophylaxis experiments, C57BL6/J (B6) mice were treated via intraperitoneal (i.p.) injection with anti-IFN-alpha/beta receptor (Ifnar1) antibody and individual ZIKV mAbs on day -1. Candidate mAbs were compared to a potently protective human mAb ZIKV-117 that we described previously⁵. An irrelevant IgG1 isotype mAb (FLU-5J8, which is specific to the influenza A virus hemagglutinin protein³³ or PBS served as a negative control. On day 0, mice were challenged via subcutaneous (s.c.) route with 10³ focus-forming units (FFU) of the ZIKV Dakar MA and monitored for 21 days for survival. High-dose prophylaxis (about 70 µg of mAb per mouse; ~5 mg/kg mAb dose)




Fig. 5. MAb protection against lethal challenge with ZIKV in mice.

a, Serum concentration of human mAbs (2 dpi) that was determined by ELISA from mice that were treated prophylactically (d-1) with indicated mAbs (9 μ g/mouse) and challenged with ZIKV (d0). Dots show measurements from individual mice (n= 5 to 14 mice per group). Mean \pm SD values are shown.

b, Serum ZIKV titers (2 dpi) from mice treated and challenged as in (a). Dots show measurements from individual mice. Mean \pm SD values are shown.

c, Survival of B6 mice that were treated and challenged as in (a). Overall difference in survival between the groups was estimated using log-rank (Mantel cox) test. P values are indicated.

d, Low dose (4.5 μ g/mouse) prophylaxis of three lead candidate mAbs ZIKV-752, -893, and -940 (n=5 mice per group), representing each of three competition-binding groups. Mice were treated and challenged as in (a). Overall difference in survival between the groups was estimated using log-rank (Mantel cox) test. P values are indicated.

e, Low-dose (9 μ g/mouse) post-exposure therapeutic efficacy (1 dpi) of three lead candidate mAbs in mice challenged with ZIKV (n= 5 mice per group). Overall difference in survival between the groups was estimated using log-rank (Mantel cox) test. P values are indicated.

Data in (a-e) represent single experiments except for ZIKV-752 and -893 in (c) that represent three independent experiments. The mAbs ZIKV-117 and FLU-5J8 or PBS served as controls. Timeline to identify the lead protective mAbs is indicated with a blue arrow in the timeline chart.

provided complete protection from mortality for three of the five tested mAbs. MAb ZIKV-668 offered partial protection, whereas mAb ZIKV-434 and FLU-5J8 or PBS treatment did not protect (**Supplementary Table 4**). Since multiple individual mAbs conferred full protection with high-dose mAb prophylaxis, we could not discriminate which mAb was the most effective *in vivo*. Therefore, we next tested a larger panel of ten neutralizing mAbs with a low-dose prophylaxis approach (using about 9 µg of mAb; 0.65 mg/kg mAb dose). Even at low doses, six of the ten human mAbs were detected readily in mouse blood as assessed on 2 dpi (**Fig. 5a**). As an early time-point correlate of mAb-mediated protection, we measured viremia from individual mice of each treatment group by qRT-PCR. All groups treated with ZIKV mAbs showed markedly (500-1,000 fold) reduced levels of virus measured as genome equivalents (GEQ) per 1 mL of serum by 2 dpi when compared to the control mAb FLU-5J8-treated group, which developed high viremia in all animals (**Fig. 5b**). This finding demonstrated efficient inhibition of viremia by a low dose of anti-ZIKV mAb in a prophylaxis setting.

Consistent with the reduced viral load in plasma, each of the tested mAbs conferred protection against disease, as shown by reduced and/or delayed mortality compared to the mAb FLU-5J8-treated control group. Three of ten tested mAbs that neutralized both Brazil and Dakar strains (ZIKV-635, -668, and - 893) conferred complete protection (100% survival by 21 dpi), with partial protection conferred by the other two neutralizing mAbs, ZIKV-752 and -940 (**Fig. 5c, Supplemental Table 4**). Protection with a 9 µg dose of ZIKV-893 or -752 was confirmed in three independent experiments. Moreover, similar protection was observed using 2 to 4-fold lower dose of ZIKV-893, -752, or -940 (**Fig. 5d**; **Supplementary Table 4**). The above results demonstrated a high level of efficacy for several of these rapidly identified mAbs against ZIKV when given as prophylaxis.

We next tested therapeutic efficacy after infection was established by administering a low dose of 9 µg of mAb per mouse on 1 dpi. We tested three mAbs ZIKV-893, -752, and -940 because of their broad and potent neutralization of ZIKV, recognition of distinct, non-overlapping epitopes on E (**Fig. 4**), and a high level of protection as prophylaxis (**Supplementary Table 4; Fig. 5a-d**). ZIKV-893 and -940 conferred complete protection that was comparable to the control human mAb ZIKV-117, whereas ZIKV-752 was partially protective (**Fig. 5e; Supplementary Table 4**). A similar level of therapeutic protection was observed using a 2-fold lower dose of ZIKV-752, -893, or -940 mAb (**Supplementary Table 4**).

In an outbreak scenario, an effective rapid public health response incorporating antibody treatments may be limited by the timeline required for protein mAb production in a format that can be safely administered to humans. Nucleic acid-encoded antibody genes offer a potential route to antibody-mediated protection with shorter delivery timelines. As such, and in parallel, we tested therapeutic potency of the twenty lead mAb candidates discovered here with antibody-encoding RNA delivery in mice using a technology that allows in vivo mAb expression after intramuscular (i.m.) delivery of an NLC-formulated RNA (J.H.E. et al., paper in preparation). Groups of B6 mice were treated with 40 µg of individual mAb-encoding RNA formulations on day -1 and then challenged with ZIKV Dakar MA on day 0. FLU-5J8- or ZIKV-117antibody-encoding RNA treated groups served as negative or positive controls, respectively. Human IgG protein was readily detected in the serum of individual mice from most treatment groups (Fig. 6a). Five mAbs that were identified to be highly protective with IgG protein treatment (ZIKV-635, -668, -752, -893, and -940) also mediated a high level of protection with this RNA antibody gene delivery method, as judged by reduced viremia on 2 dpi and survival of mice (Fig. 6b-c). These proof-of-concept experiments demonstrate the utility of an antibody-encoding RNA delivery approach for antiviral treatment against ZIKV.




Fig. 6. Protection against lethal challenge with ZIKV that was mediated by mAb-encoding RNA formulation delivery in mice.

a, Serum concentration of human mAbs (2 dpi) from mice that were treated with the indicated mAbencoding RNA formulations (40 μ g/mouse) on day -1 and challenged with ZIKV on day 0 was determined by ELISA. Dots show measurements from individual mice (n=5-10 mice per group).

b, Serum ZIKV titers (2 dpi) from mice treated and challenged as in (a) was determined by qRT-PCR. Dots show measurements from individual mice.

c, Survival of mice that were treated and challenged as in (a). Overall difference in survival between the groups was estimated using log-rank (Mantel cox) test. P values are indicated.

Data in (a-c) are from one experiment. The mAbs ZIKV-117 and FLU-5J8 served as controls. Timeline to identify the lead protective mAb-encoding RNA formulations is indicated with a blue arrow in the timeline chart.

Together, these results demonstrated the ability to identify rapidly several highly protective neutralizing mAbs against ZIKV and set the stage for evaluation of monotherapy efficacy in the rhesus macaque NHP ZIKV challenge model.

Modeling a timeline for NHP protection study against ZIKV

At the conclusion of the murine protection studies, we immediately initiated a mAb treatment study of ZIKV infection in NHPs. We produced RNA formulations using a Good Manufacturing Practice (GMP)compatible process for two lead therapeutic candidate mAbs (ZIKV-752 and -893) in a 200 mg scaledup process (Supplementary Fig. 4) that could be used in NHP studies to enable an Investigational New Drug (IND) application. For the capability demonstration in NHPs, we used our previously described potently neutralizing human mAb ZIKV-117⁵ for the challenge study. We elected to test this antibody in NHPs to maximize the utility of the data, since ZIKV-117 already is on an accelerated clinical development path. Large-scale production and purification of the ZIKV-117 IgG protein used here was not a part of the timeline. The treatment group (n=3 NHPs) received one 10 mg/kg dose of ZIKV-117 intravenously on day -1 and was challenged subcutaneously with 10³ PFU of ZIKV strain Brazil the next day. An additional group of NHPs (n=3) that received IgG of irrelevant specificity (sham) served as a control. No detectable viral RNA in plasma and other collected specimens in any of the ZIKV-117-treated NHPs (limit of detection = $2 \log_{10} (GEQ/mL)$) was observed, whereas each of the control NHPs were positive for infection (Supplementary Fig. 5a). ELISA analysis of serum from ZIKV-117 mAb-treated NHPs detected ~50 µg/mL of circulating ZIKV-117 the day after the treatment (Supplementary Fig. **5b**). Together, this timeline modeling study allowed us to define the efficacy of mAb monotherapy against ZIKV infection in NHPs in only nine days.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.12.090944; this version posted May 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Discussion

We describe an integrated technology platform pipeline modeling deployment of the rapid response for discovery of antiviral antibodies. Recently, several laboratories have demonstrated the feasibility of rapid identification of potently antiviral mAbs¹². The shortest reported time frame of which we are aware to date is about 4 months, which was reported for isolation of neutralizing mAb LCA60 against MERS-CoV, a process that included mAb identification, functional screening, mouse protection study and development of a stable cell line for mAb production³⁴. Our study demonstrated that using a pipeline of integrated technologies, human antiviral human mAb discovery and therapeutic potency verification (including mAb RNA delivery and proof-of principle NHP protection study), could be accomplished in 78 days, 12 days shorter than our 90 day goal. It should be noted that current single-cell antibody gene cloning techniques permit the rapid generation of antigen-reactive mAbs in 2 weeks or even less^{35,36}. However, isolation of mAbs that would be suitable for clinical development (e.g. mAbs with exceptional *in vitro* and *in vivo* potency), remains a bottleneck of antibody discovery process¹². We demonstrated high performance of an integrated technology platform pipeline for rapid discovery of potent human antiviral mAbs. A comparison to historical studies with previously reported human mAbs against ZIKV^{6,7,18,23} qualifies the newly identified broadly-neutralizing mAbs ZIKV-752, -893, and -940 as promising therapeutic candidates of high potency against ZIKV. In addition, these mAbs recognize diverse epitopes, which has relevance for therapeutic cocktails with complementary specificity and activity. Although a conventional mouse challenge model to assess protection against ZIKV uses long timelines (typically 16-21 days per study), early examination of viremia and a mAb dose-de-escalation approach could be used to identify highly protective mAbs in a short timeframe required by rapid response programs. Together, these results suggest that development and use of mAbs as alternative antiviral therapeutics could be practical when compared to conventional antiviral countermeasures, such as vaccines or small molecule antiviral drugs. Continuing improvement of instrument platforms for highthroughput single cell analysis (DeKosky et al., 2013; Setliff et al., 2019) warrants feasibility of rapid antibody discovery for emerging viruses in the future.

One of the remaining challenges for widespread application of antiviral antibody therapies is the potentially higher cost associated with production for intravenous administration. An alternative to passive IgG protein administration is nucleic acid delivery of genes encoding antibodies using cDNA or mRNA. A prior study showed that DNA-encoded intramuscular mAb delivery protected NHPs from ZIKV challenge after three sequential DNA administrations³⁷. Another study reported NHP protection against chikungunya virus infection after intravenous infusion of a lipid nanoparticle-encapsulated mRNA (LNP) encoding antiviral mAb³⁸, and this formulation was used in a first-in-man clinical trial of mRNA-encoded antibodies in 2019 (ClinicalTrials.gov Identifier: NCT03829384). The NLC formulation that we used in this study may have an advantage over lipid nanoparticle encapsulated RNA formulation³⁹, in that the RNA is externally bound to the nanostructured lipid carrier, as opposed to the internally placed RNA of the LNP formulation. This approach could allow for stockpiling of the stable nanoparticles without cold chain manufacturing. Thus, final formulation could be performed as needed once the desired mRNA encoding an antibody is identified and produced. Formulated RNA allows high level of mAb expression after intramuscular injection *in vivo* in mice (J.H.E. et al., paper in preparation). The extent to which these findings translate to NHPs and humans remains unclear, and this aspect of the approach must be determined in future studies. Nonetheless, our study provides a roadmap for the approach to large-scale accelerated discovery of potent antiviral human mAb therapeutics against known viral antigens and sets the stage for pre-clinical evaluation of mAbs using RNA delivery platforms.

Methods

Research subjects

We studied seven subjects in the United States with previous or recent ZIKV infection (**Supplementary Table 1**). The studies were approved by the Institutional Review Board of Vanderbilt University Medical Center; samples were obtained after written informed consent was obtained by the Vanderbilt Clinical Trials Center. Subjects were infected during the 2015-2016 outbreak of an Asian lineage strain, following exposure in Brazil, Nicaragua, Puerto Rico, Dominican Republic, Guatemala or Haiti.

Animals

Mouse challenge studies were approved by the Washington University School of Medicine (Assurance number A3381-01) Institutional Animal Care and Use Committee. The facility where animal studies were conducted is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International and follows guidelines set forth by the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011. Blood was obtained as approved by submandibular vein bleeding. Virus inoculations were performed under anesthesia that was induced and maintained with ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering. Mice were non-specifically and blindly distributed into respective groups.

The NHP research studies adhered to principles stated in the eighth edition of the Guide for the Care and Use of Laboratory Animals. The facility where this research was conducted [(Alpha Genesis Incorporated, Yemassee, SC)] is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International and has an approved Office of Laboratory Animal Welfare Assurance (A3645-01).

Cell culture

Vero cells (American Type Culture Collection) were maintained at 37°C in 5% CO₂ in Dulbecco's minimal essential medium (DMEM) containing 10% (vol/vol) heat-inactivated fetal bovine serum (FBS) and 1 mM sodium pyruvate. All cell lines were tested and found negative for mycoplasma contamination.

Viruses

Previously described human isolates of ZIKV Brazil, Paraiba 01/2015 (GenBank: KX280026.1)^{21,40}, and ZIKV Dakar 41525, Senegal 1984 (GenBank: KU955591)²⁰ were used for *in vitro* studies. A previously described mouse-adapted isolate of ZIKV Dakar 41525²⁰ ZIKV Dakar MA (GenBank: MG758786.1), was used for both *in vitro* and *in vivo* studies. For NHP studies a human ZIKV strain from Brazil (Brazil 2015) was used^{41,42}.

Virus stock production

To identify cells suitable for production of high-titer ZIKV stocks in an antigen-independent manner, we used qRT-PCR to rapidly detect ZIKV viral RNA in a panel of immortalized cell lines including those commonly used for virus propagation (Vero, BHK, JEG-3, HeLa, HEK-293T, U20S, A549, Huh7, Huh7.5, EA.Hy926, and Hap-1 cell lines). For subsequent ZIKV production studies, we chose Vero cells due to their well-characterized use in virus production. To generate stocks of ZIKV for subsequent *in vitro* and *in vivo* studies, Vero cells plated in T175 flasks were inoculated with a seed stock and cell culture supernatant collected 66 to 72 hrs after inoculation and titrated. Virus stocks were then titrated by focus forming assay (FFA), aliquoted, and stored at -80°C until use. To identify conditions suitable for large-scale production of ZIKV stocks in Vero cells grown in roller bottles, we examined ZIKV titers in

various serum concentrations ranged from 0.5 to 5% of FBS in cell culture supernatant collected 24 to 72 hrs after inoculation. We observed that even 0.5% fetal bovine serum was sufficient to generate hightiter ZIKV stocks by 72 hrs after virus inoculation. To identify conditions for concentration and inactivation of virus stocks, we determined the infectivity of ZIKV stocks by FFA following ultracentrifugation as previously described⁴³ and following inactivation with hydrogen peroxide in an attempt to preserve immunogenicity as described previously⁴⁴. We observed increased ZIKV titers in the virus pellet following ultra-centrifugation and could not detect infectious ZIKV following treatment with 3% hydrogen peroxide for 1 h at ambient temperature and 0.024 U/µL of catalase for 10 min at ambient temperature (to inactivate hydrogen peroxide).

Human subjects selection and target-specific memory B cells isolation

B cell responses to ZIKV in PBMCs from a cohort of 11 subjects with previous exposure to the ZIKV Asian lineage were assessed to identify subjects with the highest response. The frequency of ZIKV-specific B cells was enumerated from frozen PBMCs using an African ZIKV lineage soluble recombinant E protein (Meridian Bioscience), the antigen that was used previously to identify potent ZIKV mAbs⁵. Briefly, B cells were purified magnetically (STEMCELL Technologies) and stained with anti-CD19, -IgD, -IgM, and -IgA phenotyping antibodies (BD Biosciences) and biotinylated E protein. 4',6-diamidino-2-phenylindole (DAPI) was used as a viability dye to discriminate dead cells. Antigen-labeled class-switched memory B cell-E complexes (CD19⁺IgM⁻IgD⁻IgA⁻ZIKV E⁺DAPI⁻) were detected with allophycocyanin (APC)-labeled streptavidin conjugate and quantified using an iQue Plus Screener flow cytometer (IntelliCyt Corp). After identification of the seven subjects with the highest B cell response against ZIKV, target-specific memory B cells were isolated by FACS using an SH800 cell sorter (Sony) from pooled PBMCs of these subjects, after labeling of B cells with biotinylated E protein (sub-panel 1).

Although sorting with a biotinylated E antigen was used successfully for isolation of human neutralizing ZIKV mAbs, this approach might fail to identify mAbs whose antigenic sites altered by the biotin labeling of the target protein. To overcome this limitation, we also used alternate approaches. The second approach used binding to soluble intact E protein antigen, but included a labeled antibody detected at the E fusion loop (FL) (indirect label method, sub-panel 2). This approach circumvented any binding issues stemming from biotin-labeling as well as excluded the subset of B cells that encode FL-specific mAbs, which dominate in the response to ZIKV but typically poorly neutralize the virus⁵. Third, all labeled B cells (as in the mAb sub-panel 2) and a subset of high-affinity B cells (high E labeling clones, mAb subpanel 3) were sorted separately. Overall, from $> 5 \times 10^8$ PBMCs, > 5,000 E-specific B cells were sorted and subjected to further analysis. Two methods were implemented for the preparation of sorted B cells for sequencing. Approximately 800 sorted cells were subjected to direct sequencing immediately after FACS. The remaining cells were expanded in culture for eight days in the presence of irradiated 3T3 feeder cells that were engineered to express human CD40L, IL-21, and BAFF as described previously⁴⁵. The expanded lymphoblastoid cell lines (LCLs) secreted high levels of E-specific mAbs, as confirmed by ELISA from culture supernatants. Approximately 40,000 expanded LCLs were sequenced using the Chromium sequencing method (10x Genomics).

Generation of single cell antibody variable genes profiling libraries

The Chromium Single Cell V(D)J workflow with B-cell only enrichment option was chosen for generating linked heavy-chain and light-chain antibody profiling libraries. Approximately 800 directly sorted E-specific B cells were split evenly into two replicates and separately added to 50 μ L of RT Reagent Mix, 5.9 μ L of Poly-dt RT Primer, 2.4 μ L of Additive A and 10 μ L of RT Enzyme Mix B to

complete the Reaction Mix as per the vendor's protocol, which then was loaded directly onto a Chromium chip (10x Genomics). Similarly, for the remaining sorted cells that were bulk expanded, approximately 40,000 cells from two separate sorting approaches were split evenly across six reactions and separately processed as described above before loading onto a Chromium chip. The libraries were prepared following the User Guide for Chromium Single Cell V(D)J Reagents kits (CG000086_REV C).

NGS sequencing

Chromium Single Cell V(D)J B-Cell enriched libraries were quantified, normalized and sequenced according to the User Guide for Chromium Single Cell V(D)J Reagents kits (CG000086_REV C). The two enriched libraries from direct flow cytometric cell sorting were combined into one library pool and sequenced on a NovaSeq sequencer (Illumina) with a NovaSeq 6000 S1 Reagent Kit (300 cycles) (Illumina). The six enriched libraries from bulk expansion were combined into one library pool and sequenced on a NovaSeq sequencer with a NovaSeq 6000 S4 Reagent Kit (300 cycles (Illumina). All enriched V(D)J libraries were targeted for sequencing depth of at least 5,000 raw read pairs per cell. Following sequencing, all samples were demultiplexed and processed through the 10x Genomics Cell Ranger software (version 2.1.1) as detailed below.

Bioinformatics analysis

The down-selection to identify lead candidates for expression was carried out in two phases. In the first phase, all paired antibody heavy and light chain variable gene cDNA nucleotide sequences obtained that contained a single heavy and light chain sequence were processed using our Python-based antibody variable gene analysis tool (PyIR; https://github.com/crowelab/PyIR) (C.S. et al., paper in preparation). We considered heavy and light chain encoding gene pairs productive and retained them for additional downstream processing if they met the following criteria: 1) did not contain a stop codon, 2) had an intact

CDR3 and 3) contained an in-frame junctional region. The second phase of processing grouped all productive heavy chain nucleotide sequences based on their V3J clonotype (defined by identical inferred V and J gene assignments and identical amino acid sequences of the CDR3)⁴⁶. All heavy chain nucleotide sequences from individual sub-panels were grouped by their heavy chain V3J clonotype. The somatic variants belonging to each heavy chain V3J clonotype grouping then were rank-ordered based on the degree of somatic mutation, and only the most mutated heavy chain sequence was retained for downstream expression and characterization. Any somatic variant that was not designated as an IgG isotype (based on the sequence and assignment using the 10x Genomics Cellranger V(D)J software [version 2.1.1]) was removed from consideration. All heavy and light chain nucleotide sequences were translated, and redundant entries removed to avoid expressing identical mAbs. The identities of antibody variable gene segments, CDRs, and mutations from inferred germline gene segments were determined by alignment using the ImMunoGeneTics database⁴⁷.

Antibody gene synthesis

Sequences of selected mAbs were synthesized using a rapid high-throughput cDNA synthesis platform (Twist Bioscience) and subsequently cloned into an IgG1 monocistronic expression vector (designated as pTwist) for mammalian cell culture mAb secretion. This vector contains an enhanced 2A sequence and GSG linker that allows simultaneous expression of mAb heavy and light chain genes from a single construct upon transfection ²⁵.

MAb production and purification

For high-throughput production of recombinant mAbs, we adopted approaches designated as "micro-scale". For mAbs expression, we performed micro-scale transfection (~1 mL per antibody) of Chinese

hamster ovary (CHO) cell cultures using the GibcoTM ExpiCHOTM Expression System and a protocol for deep 96-well blocks (ThermoFisher Scientific). Briefly, synthesized antibody-encoding lyophilized DNA (~2 µg per transfection) was reconstituted in OptiPro serum free medium (OptiPro SFM), incubated with ExpiFectamine CHO Reagent and added to 800 µL of ExpiCHO cell cultures into 96 deep well blocks using a ViaFlo 384 liquid handler (Integra Biosciences). Plates were incubated on an orbital shaker at 1,000 rpm with 3 mm orbital diameter at 37°C in 8% CO₂. The next day after transfection, ExpiFectamine CHO Enhancer and ExpiCHO Feed reagents were added to the cells, followed by 4 days incubation for a total of 5 days at 37°C in 8% CO₂. Culture supernatants were harvested after centrifugation of blocks at 450 x g for 5 min and stored at 4°C until use. For highthroughput micro-scale mAbs purification, we used fritted deep well plates containing 25 µL of settled protein G resin (GE Healthcare Life Sciences) per well. Clarified culture supernatants were incubated with protein G resin for mAb capturing, washed with PBS using a 96-well plate manifold base (Qiagen) connected to the vacuum, and eluted into 96-well PCR plates using 86 µL of 0.1 M glycine-HCL buffer pH 2.7. After neutralization with 14 µL of 1 M Tris-HCl pH 8.0, purified mAbs were buffer exchanged into PBS using Zeba[™] Spin Desalting Plates (ThermoFisher Scientific) and stored at 4°C until use.

For scaling up of mAb production for *in vivo* mouse studies, the transfection was performed in 125 mL Erlenmeyer vented cap flasks (Corning) containing 35 mL of ExpiCHO cells following the manufacturer's protocol. Antibodies were purified from filtered culture supernatants by fast protein liquid chromatography (FPLC) on an ÄKTA Pure instrument using a HiTrap MabSelect Sure column (GE Healthcare Life Sciences). Purified mAbs were buffer exchanged into PBS, filtered using sterile 0.45-µm pore size filter devices (Millipore), concentrated, and stored in aliquots at 4°C until use. To

quantify purified mAbs, absorption at 280 nm (A280) was measured using NanoDrop (ThermoFisher Scientific), and mAb concentration was calculated using IgG sample type setting on NanoDrop that uses a typical for IgG molar extinction coefficient equal to 210,000 M⁻¹cm⁻¹.

Antibody-encoding RNA production

cDNAs encoding the 20 lead mAb candidates were amplified from the mammalian expression pTwist vector using universal primer sets and cloned into plasmids encoding Venezuelan equine encephalitis virus replicon (strain TC-83) under the control of a T7 promoter (pT7-VEE-Rep)³². To generate linear templates for RNA transcription for RNA *in vitro* transcription and capping at midi scale (500 µg), plasmid DNA was cut by restriction digest using NotI or BspQI enzymes (New England Biolabs), respectively, and purified using phenol chloroform extraction and sodium acetate precipitation. RNA was transcribed using T7 Polymerase, RNAse inhibitor, Pyrophosphatase enzymes (Aldevron) and reaction buffer. RNA transcripts were capped with vaccinia virus capping enzyme using GTP and S-adenosyl-methionine (Aldevron) as substrates to create a cap-0 structure. RNA was purified using lithium chloride precipitation. Large-scale capability demonstration RNA production was performed using a 200 mg scaled-up process and purified via column on a Capto Core 700 instrument (GE Healthcare Life Sciences) and tangential flow filtration.

RNA formulation production

The nanostructured lipid carrier (NLC) nanoparticle formulation was manufactured as previously described ³². The oil phase is composed of squalene (the liquid-phase of the oil core), glyceryl trimyristate (Dynasan® 114) (the solid-phase of the oil core), a non-ionic sorbitan ester surfactant [sorbitan monostearate (Span® 60)], and the cationic lipid DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-

N,N,N-trimethylammonium chloride). The aqueous phase is a 10 mM sodium citrate trihydrate buffer containing the non-ionic PEGylated surfactant Tween® 80. Separately, the two phases were heated and equilibrated to 60°C in a bath sonicator. Following complete dissolution of the solid components, the oil and aqueous phases were mixed at 5,000 rpm in a high-speed laboratory emulsifier (Silverson Machines, Inc.) to produce a crude mixture containing micron-sized oil droplets. Further particle size reduction was achieved by high-shear homogenization in a M-110P microfluidizer (Microfluidics, Corp.). The colloid mixtures were processed at 30,000 psi for five discrete microfluidization passes. The final pH was adjusted to between 6.5 and 6.8. Formulations were filtered with a 0.2 µm polyethersulfone membrane syringe filter and stored at 2 to 8°C. RNA was complexed with NLC at a nitrogen-to-phosphate ratio of 5, diluting NLC in 10 mM citrate buffer and RNA in a 20% sucrose solution and complexing on ice for 30 min prior to use.

ELISA binding screening assays

Wells of 96-well microtiter plates were coated with purified recombinant ZIKV E protein (Meridian Bioscience) at 4°C overnight. Plates were blocked with 2% non-fat dry milk and 2% normal goat serum in DPBS containing 0.05% Tween-20 (DPBS-T) for 1 hr. For mAb screening assays, CHO cell culture supernatants or purified mAbs were diluted 1:20 in blocking buffer, added to the wells, and incubated for 1 hr at ambient temperature. The bound antibodies were detected using goat anti-human IgG conjugated with HRP (horseradish peroxidase) (Southern Biotech) and TMB (3,3',5,5'-tetramethylbenzidine) substrate (ThermoFisher Scientific). Color development was monitored, 1N hydrochloric acid was added to stop the reaction, and the absorbance was measured at 450 nm using a spectrophotometer (Biotek). For dose-response assays, serial dilutions of purified mAbs were applied to the wells in triplicate or quadruplicate, and mAb binding was detected as detailed above.

Focus reduction neutralization test

Serial dilutions of mAbs were incubated with 10² FFU of different ZIKV strains (Dakar or Brazil) for 1 h at 37°C. The mAb–virus complexes were added to Vero cell monolayers in 96-well plates for 90 min at 37°C. Subsequently, cells were overlaid with 1% (w/v) methylcellulose in Minimum Essential Medium (MEM) supplemented with 4% heat-inactivated FBS. Plates were fixed 40 hrs later with 1% paraformaldehyde (PFA) in PBS for 1 h at room temperature. The plates were incubated sequentially with 500 ng/mL previously described mouse anti-ZIKV mAb ZV-16⁵ and horseradish-peroxidase (HRP)-conjugated goat anti-mouse IgG in PBS supplemented with 0.1% (w/v) saponin (Sigma) and 0.1% bovine serum albumin (BSA). ZIKV-infected cell foci were visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot 5.0.37 Macro Analyzer (Cellular Technologies).

High-throughput mAbs quantification

High-throughput quantification of micro-scale produced mAbs was performed from CHO culture supernatants or micro-scale purified mAbs in a 96-well plate format using the Cy-Clone Plus Kit and an iQue Plus Screener flow cytometer (IntelliCyt Corp), according to the vendor's protocol. Purified mAbs were assessed at a single dilution (1:10 final, using 2 μ L of purified mAb per reaction), and a control human IgG solution with known concentration was used to generate a calibration curve. Data were analyzed using ForeCyt software version 6.2 (IntelliCyt Corp).

Real-time cell analysis assay (RTCA)

To screen for neutralizing activity in the panel of recombinantly expressed mAbs, we used a highthroughput and quantitative real-time cell analysis (RTCA) assay and xCelligence Analyzer (ACEA Biosciences Inc.) that assesses kinetic changes in cell physiology, including virus-induced cytopathic effect (CPE). Fifty (50) µL of cell culture medium (DMEM supplemented with 2% FBS) was added to each well of a 96-well E-plate using a ViaFlo384 liquid handler (Integra Biosciences) to obtain background reading. Eighteen thousand (18,000) Vero-E6 cells in 50 µL of cell culture medium were seeded per each well, and the plate was placed on the analyzer. Measurements were taken automatically every 15 min, and the sensograms were visualized using RTCA software version 2.1.0 (ACEA Biosciences Inc). For a screening neutralization assay, the virus (0.5 MOI, ~9,000 PFU per well) was mixed with a 1:10 dilution of CHO supernatants obtained from micro-scale expression experiments, or a 1:25 dilution of micro-scale purified Abs in a total volume of 50 µL using DMEM supplemented with 2% FBS as a diluent and incubated for 1 h at 37°C in 5% CO₂. At ~12 hrs after seeding the cells, the virus-mAb mixtures were added in replicates to the cells in 96-well E-plates. Wells containing virus only (in the absence of mAb) and wells containing only Vero cells in medium were included as controls. Plates were measured continuously (every 15 minutes) for 48 to 72 hrs to assess virus neutralization. A mAb was considered as neutralizing if it partially or fully inhibited ZIKV-induced CPE. For mAb potency ranking experiments, individual mAbs identified as fully neutralizing from the screening study were assessed at six five-fold dilutions starting from 1 µg/mL in replicates after normalization of mAb concentrations. IC_{50} values were estimated as cellular index (CI) change over time, using non-linear fit with variable slope analysis performed in the RTCA software version 2.1.0 (ACEA Biosciences Inc.). The potency ranking study was repeated using midi-scale purified mAbs to confirm the activity and to assure the quality of antibody preparations before performing *in vivo* protection studies in mice.

Antibody-mediated cellular phagocytosis by human monocytes (ADCP)

Recombinant soluble ZIKV E protein was biotinylated and coupled to AF488 Neutravidin beads (Life Technologies). Microscale-purified mAbs were tested at a single 1:10 dilution; concentrations were not normalized. Antibodies were diluted in cell culture medium and incubated with beads for 2 h at 37°C. THP-1 monocytes (ATCC) were added at 2.5 x 10⁴ cells per well and incubated for 18 h at 37°C. Cells were fixed with 4% PFA and analyzed on a BD LSRII flow cytometer, and a phagocytic score was determined using the percentage of AF488⁺ cells and the MFI of the AF488⁺ cells. The previously identified human mAb ZIKV-117 was used as a positive control, and human mAb FLU-5J8 was used as a negative control.

Antibody-mediated neutrophil phagocytosis (ADNP)

Recombinant soluble ZIKV E protein was biotinylated and coupled to AF488 Neutravidin beads (Life Technologies). Microscale-purified mAbs were tested at a single 1:10 dilution; concentrations were not normalized. Antibodies were diluted in cell culture medium and incubated with beads for 2 hrs at 37°C. White blood cells were isolated from the peripheral blood of subjects by lysis of red blood cells, followed by three washes with PBS. Cells were added at a concentration of 5.0×10^4 cells/well and incubated for 1 hr at 37°C. Cells were stained with CD66b (Pacific Blue, Clone G10F5; BioLegend), CD3 (AF00, Clone UCHT1; BD Biosciences), and CD14 (APC-Cy7, Clone M ϕ P9; BD Biosciences), and fixed with 4% PFA, and analyzed by flow cytometry on a BD LSR II flow cytometer. Neutrophils were defined as SSC-A^{high} CD66b+, CD3-, CD14-. A phagocytic score was determined using the percentage of AF488⁺ cells and the MFI of the AF488⁺ cells. The previously identified mAb ZIKV-117 was used as a positive control, and mAb FLU-5J8 was used as a negative control.

Antibody-mediated complement deposition (ADCD)

Recombinant soluble ZIKV E protein was biotinylated and coupled to red fluorescent Neutravidin beads (Life Technologies). Antibodies were diluted to 5 µg/mL in RPMI-1640, and incubated with GP-coated beads for 2 h at 37°C. Freshly reconstituted guinea pig complement (Cedarlane Labs) was diluted in veronal buffer with 0.1% fish gelatin (Boston Bioproducts), added to the antibody-bead complexes, and incubated for 20 min at 37°C. Beads were washed twice with PBS containing 15 mM EDTA, and stained with an anti-guinea pig C3 antibody conjugated to FITC (MP Biomedicals) for 15 min at ambient temperature. Beads were washed twice more with PBS, and C3 deposition onto beads was analyzed on a BD LSRII flow cytometer and the median fluorescence intensity of the FITC+ of all beads was measured.

Competition-binding analysis and epitope mapping

For the competition-binding assay, wells of 384-well microtiter plates were coated with purified recombinant ZIKV E protein at 4°C overnight. Plates were blocked with 2% BSA in DPBS containing 0.05% Tween-20 (DPBS-T) for 1 hr. Purified unlabeled mAbs were diluted in blocking buffer to 5 μ g/mL, added to the wells (25 μ L/well), and incubated for 1 h at ambient temperature. Biotinylated previously characterized ZIKV E-specific human mAbs ZIKV-117, ZIKV-116, and ZIKV-88 were added to indicated wells at 5 μ g/mL in a 2.5 μ L/well volume (final ~0.5 μ g/mL concentration of biotinylated mAb) without washing of unlabeled antibody and then incubated for 1 h at ambient temperature. Plates were washed, and bound antibodies were detected using HRP-conjugated avidin (Sigma) and TMB substrate. The signal obtained for binding of the biotin-labeled reference antibody in the presence of the unlabeled tested antibody was expressed as a percentage of the binding of the reference antibody alone after subtracting the background signal. Tested mAbs were considered competing if their presence reduced the reference antibody binding to less than 41% of its maximal

binding and non-competing if the signal was greater than 71%. A level of 40–70% was considered intermediate competition.

Epitope mapping was performed by shotgun mutagenesis essentially as described previously⁴⁸. A ZIKV prM/E protein expression construct (based on ZIKV strain SPH2015) was subjected to highthroughput alanine scanning mutagenesis to generate a comprehensive mutation library. Each residue within prM/E was changed to alanine, with alanine codons mutated to serine. In total, 672 ZIKV prM/E mutants were generated (100% coverage), sequence confirmed, and arrayed into 384-well plates. Each ZIKV prM/E mutant was transfected into HEK-293T cells and allowed to express for 22 hrs. Cells were fixed in 4% (v/v) paraformaldehyde (Electron Microscopy Sciences), and permeabilized with 0.1% (w/v) saponin (Sigma-Aldrich) in PBS plus calcium and magnesium (PBS++). Cells were incubated with purified mAbs diluted in PBS++, 10% normal goat serum (Sigma), and 0.1% saponin. Primary antibody screening concentrations determined independent were using an immunofluorescence titration curve against wild-type ZIKV prM/E to ensure that signals were within the linear range of detection. Antibodies were detected using 3.75 µg/mL of AlexaFluor488conjugated secondary antibody (Jackson ImmunoResearch Laboratories) in 10% normal goat serum with 0.1% saponin. Cells were washed three times with PBS++/0.1% saponin followed by two washes in PBS. Mean cellular fluorescence was detected using a high-throughput flow cytometer (HTFC, Intellicyt Corp.). Antibody reactivity against each mutant prM/E clone was calculated relative to wildtype prM/E protein reactivity by subtracting the signal from mock-transfected controls and normalizing to the signal from wild-type prM/E-transfected controls. Mutations within clones were identified as critical to the mAb epitope if they did not support reactivity of the test MAb, but supported reactivity of other ZIKV antibodies. This counter-screen strategy facilitates the exclusion of prM/E mutants that are locally misfolded or have an expression defect.

Detection of circulating human mAbs in mouse serum

The amount of human mAb in serum was detected using a capture ELISA with a standard curve of recombinant anti-ZIKV mAb ZIKV-117 or an IgG1 isotype-matched control anti-influenza mAb, FLU-5J8. Briefly, plates were coated with 2 µg/mL of goat anti-human kappa or goat anti-human lambda antibodies cross-absorbed against mouse IgG (Southern Biotech) at 4°C overnight. Plates were blocked using 2% BSA in PBS for 1 h at 37°C and then incubated for 1 h at 4°C with serial dilutions of heat-inactivated mouse serum in parallel with a serial dilution of a known quantity of ZIKV-117 hIgG1 protein. After washing, bound antibody was detected using HRP-conjugated goat anti-human Fc multiple species cross-absorbed (Southern Biotech) for 1 h at 4°C. Plates were developed using TMB substrate (Thermo Fisher Scientific), and the reaction was stopped with H₂SO₄. ELISA plates were read using a TriBar LB941 plate reader (Berthold Technologies). The optical density values from the known quantity of ZIKV-117 hIgG1 were fitted to a standard curve and compared to the optical density values of serum to determine the concentration of ZIKV-117 hIgG1.

ZIKV titer measurements

Blood was collected from ZIKV-infected mice at various time points, allowed to clot at ambient temperature, and serum was separated by centrifugation. Viral RNA was isolated using the 96-well Viral RNA kit (Epigenetics), as described by the manufacturer. ZIKV RNA levels were determined by TaqMan one-step qRT-PCR, as described previously⁴⁹. Alternatively, ZIKV Dakar MA and Brazil strain titers were determined by FFA on Vero cell monolayer cultures, as previously described⁵⁰.

Mouse challenge experiments

Wild-type C57BL/6J mice (4 weeks of age) were purchased from Jackson Laboratory. For studies involving ZIKV challenge, mice were treated with 2 mg of an Ifnar1-blocking antibody (MAR1-5A3, Leinco Technologies) by i.p. injection one-day before virus inoculation. For prophylaxis experiments, mice were treated i.p. one day before virus challenge with purified individual mAbs and monitored for 21 days for survival. For therapeutic protection experiments, mice were treated i.p. one day after virus challenge with varying defined doses of purified individual Abs and monitored for 21 days for survival. For antibody-encoding RNA delivery studies, mice were inoculated with 40 µg of individual RNA by an i.m. route (into each quadricep and hamstring muscle groups) one day before virus challenge, with four injections of 50 µL of RNA/NLC complex per injection. For ZIKV infections, mice were inoculated by a subcutaneous (via footpad) route with 10³ FFU of ZIKV Dakar MA in a volume of 30 µL of PBS. Antibody ZIKV-117 was used as a positive control, and mAb FLU-5J8 or PBS were used as a negative control.

NHP challenge study

Six healthy adult rhesus macaques (*Macaca mulatta*) of Chinese origin (5 to 15 kg body weight) were studied. Animals were allocated randomly to two treatment groups (n=3 per group) and two control ("sham"-treated) groups (n=3 per group). All animals were inoculated by subcutaneous (s.q). route with a target dose of 10⁶ viral particles (approx. 10³ PFU) of ZIKV Brazil prior to mAb infusions. The macaques in the treatment group received 10 mg/kg of ZIKV-117 mAb by intravenous injection one day prior ZIKV challenge. The control sham-treated animals received 10 mg/kg of mAb PGT121 that is specific to gp120 protein antigen of HIV-1 one day prior ZIKV challenge. All animals were given physical exams, and blood was collected at the time of ZIKV inoculation and at indicated times after

ZIKV inoculation. In addition, all animals were monitored daily with an internal scoring protocol approved by the Institutional Animal Care and Use Committee. These studies were not blinded.

Detection of virus load in NHPs by qRT-PCR analysis

Titration of virus in indicated specimens was performed by qRT-PCR analysis as previously described^{41,42}. Viral RNA was isolated from plasma and other tested specimens with a QIAcube HT (QIAGEN, Germany). A QIAcube 96 Cador Pathogen kit or RNeasy 96 QIAcube HT kit were used for RNA extraction. A cDNA of the wild-type BeH815744 Cap gene was cloned into the pcDNA3.1 expression plasmid, then transcribed *in vitro* to RNA using the AmpliCap-Max T7 High Yield Message Maker Kit (Cellscript). RNA quality was assessed by the Beth Israel Deaconess Medical Center molecular core facility. Ten-fold dilutions of the RNA were prepared for standards and reverse transcribed to cDNA. Primers were synthesized by Integrated DNA Technologies (Coralville), and probes were obtained from Biosearch Technologies (Petaluma). Viral loads were calculated as virus particles (VP) per mL, and the assay sensitivity was 100 copies/mL.

Detection of circulating human mAbs in NHP serum

A modified protocol using a commercially available human anti-zika virus Envelope protein (ZIKV-Env) IgG kit (Alpha Diagnostics International) was used to quantify ZIKV-117 mAb levels in NHP serum samples. In brief, plate wells were equilibrated several times with kit NSB wash buffer and 100 μ L of standard calibrators, and NHP serum dilutions were prepared in kit sample diluent buffer plated in duplicate and incubated for 1 h at ambient temperature. Plates were washed and NHP IgG preadsorbed HRP-conjugated anti-human secondary antibodies (Novus Biological) diluted to 1:2,000 in kit sample diluent buffer was added at 100 μ L/well and incubated for 1 h. Plates were washed and developed for two minutes using the kit TMB solution, stopped by addition of kit stop solution and analyzed at 450 nm/550 nm on a Versamax microplate plate reader (Molecular Devices) using Softmax Pro 6.5.1 software. A four-parameter logistic (4-PL) standard curve was generated using Prism v8.0 software (GraphPad) for the standard calibrators, and the concentrations of the unknown samples were interpolated from the linear portion of the curve.

Quantification and statistical analysis

The descriptive statistics mean \pm SEM or mean \pm SD were determined for continuous variables as noted. Survival curves were estimated using the Kaplan-Meier method, and an overall difference between groups was estimated using the two-sided log rank test (Mantel-Cox) with subjects right censored, if they survived until the end of the study. In FRNT neutralization assays, IC₅₀ values were calculated after log transformation of antibody concentrations using a 3-parameter nonlinear fit analysis. In the RTCA neutralization assays, IC₅₀ values were estimated as cellular index change over time using non-linear fit with variable slope analysis determined in the RTCA software version 2.1.0 (ACEA Biosciences Inc.). Technical and biological replicates are described in the figure legends. Statistical analyses were performed using Prism v7.2 (GraphPad).

Acknowledgements

We thank M. Mayo for assistance with acquisition of the human survivor samples and coordination across study sites, J. Govero for assistance with RNA protection experiments, A. Jones and K. Beeri for assistance and coordination of NGS sequencing timelines, J.C. Slaughter, M. Goff and R. Troseth for assistance with data analysis, STEMCELL Technologies and ACEA Biosciences for providing resources. This study was supported by Defense Advanced Research Projects Agency (DARPA) grant HR0011-18-

2-0001 and HHS contract HHSN272201400058C (to J.E.C. and B.J.D.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the DARPA.

Contributions

P.G., R.G.B., J.H.E, R.N., C.S., T. J. S., E.D., B.J.D., T.J.S., L.T., G.A., S.G. R., N.V.H., D.H.B., M.S.D., J.E.C., L.B.T. and R.C. planned the studies. P.G., R.G.B., J.H.E., Q. T., R.N., C.S., T.J., L.A.D., A.K., J.A., J.L., M.E.F., P.A., E.L., S.E., B.G., J.F.S., V.R., T.B., T.C.L., C.H.L., and J.N. conducted experiments, P.G., E.D., R.G.B., J.H.E., C.S., T.J.S., M.J.G., N.V.H., M.S.D., J.E.C. L.B.T. and R.C. interpreted the studies. P.G., J.E.C., and R.C. wrote the first draft of the paper. B.J.D., G.A., S.G.R., D.H.B., M.S.D., and J.E.C. obtained funding. All authors reviewed, edited and approved the paper.

Competing interests

J.L., E.D., M.E.F., and B.J.D. are employees of Integral Molecular. B.J.D. is a shareholder of Integral Molecular. G.A. has a financial interest in SeromYx, a company developing platform technology that describes the antibody immune response. G.A. interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. M.S.D. is a consultant for Inbios and Emergent BioSolutions and on the Scientific Advisory Board of Moderna. J.E.C. has served as a consultant for Sanofi and is on the Scientific Advisory Boards of CompuVax and Meissa Vaccines, is a recipient of previous unrelated research grants from Moderna and Sanofi and is founder of IDBiologics. JHE, APK, and NVH are inventors on a patent application describing the NLC formulation. Vanderbilt University has applied for a patent concerning ZIKV antibodies that is related to this work. All other authors declared no competing interests.

Data availability

All relevant data are included with the manuscript.

REFERENCES

- 1 Sok, D. & Burton, D. R. Recent progress in broadly neutralizing antibodies to HIV. *Nat Immunol* **19**, 1179-1188, doi:10.1038/s41590-018-0235-7 (2018).
- Laursen, N. S. & Wilson, I. A. Broadly neutralizing antibodies against influenza viruses.
 Antiviral Res 98, 476-483, doi:10.1016/j.antiviral.2013.03.021 (2013).
- 3 Bornholdt, Z. A. *et al.* Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. *Science* **351**, 1078-1083, doi:10.1126/science.aad5788 (2016).
- 4 Flyak, A. I. *et al.* Mechanism of human antibody-mediated neutralization of Marburg virus. *Cell* **160**, 893-903, doi:10.1016/j.cell.2015.01.031 (2015).
- 5 Sapparapu, G. *et al.* Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. *Nature* **540**, 443-447, doi:10.1038/nature20564 (2016).
- 6 Stettler, K. *et al.* Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. *Science* **353**, 823-826, doi:10.1126/science.aaf8505 (2016).
- 7 Wang, Q. *et al.* Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. *Science translational medicine* **8**, 369ra179, doi:10.1126/scitranslmed.aai8336 (2016).
- 8 Robinson, J. E. *et al.* Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. *Nature communications* **7**, doi:ARTN 11544. 10.1038/ncomms11544 (2016).
- 9 Corti, D., Passini, N., Lanzavecchia, A. & Zambon, M. Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. *J Infect Public Health*

9, 231-235, doi:10.1016/j.jiph.2016.04.003 (2016).

- 10 Gilchuk, I. *et al.* Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. *Cell* **167**, 684-694 e689, doi:10.1016/j.cell.2016.09.049 (2016).
- Geisbert, T. W. *et al.* Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. *Science translational medicine* 6, 242ra282, doi:10.1126/scitranslmed.3008929 (2014).
- 12 Walker, L. M. & Burton, D. R. Passive immunotherapy of viral infections: 'superantibodies' enter the fray. *Nat Rev Immunol* **18**, 297-308, doi:10.1038/nri.2017.148 (2018).
- 13 Salazar, G., Zhang, N., Fu, T. M. & An, Z. Antibody therapies for the prevention and treatment of viral infections. *NPJ Vaccines* **2**, 19, doi:10.1038/s41541-017-0019-3 (2017).
- 14 Coltart, C. E., Lindsey, B., Ghinai, I., Johnson, A. M. & Heymann, D. L. The Ebola outbreak, 2013-2016: old lessons for new epidemics. *Philos Trans R Soc Lond B Biol Sci* **372**, 1-24, doi:10.1098/rstb.2016.0297 (2017).
- Sikka, V. *et al.* The emergence of zika virus as a global health security threat: A review and a consensus statement of the INDUSEM Joint working Group (JWG). *J Glob Infect Dis* 8, 3-15, doi:10.4103/0974-777x.176140 (2016).
- 16 Pierson, T. C. & Diamond, M. S. The emergence of Zika virus and its new clinical syndromes. *Nature* **560**, 573-581, doi:10.1038/s41586-018-0446-y (2018).
- 17 Musso, D. & Gubler, D. J. Zika Virus. *Clin Microbiol Rev* **29**, 487-524, doi:10.1128/CMR.00072-15 (2016).

- 18 Robbiani, D. F. *et al.* Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. *Cell* **169**, 597-609 e511, doi:10.1016/j.cell.2017.04.024 (2017).
- 19 Magnani, D. M. *et al.* Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. *Science translational medicine* **9**, doi:10.1126/scitranslmed.aan8184 (2017).
- 20 Gorman, M. J. *et al.* An Immunocompetent Mouse Model of Zika Virus Infection. *Cell host & microbe* **23**, 672-685 e676, doi:10.1016/j.chom.2018.04.003 (2018).
- Zhao, H. *et al.* Structural Basis of Zika Virus-Specific Antibody Protection. *Cell* 166, 1016-1027, doi:10.1016/j.cell.2016.07.020 (2016).
- Slon-Campos, J. L. *et al.* A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. *Nat Immunol* 20, 1291-1298, doi:10.1038/s41590-019-0477-z (2019).
- 23 Rogers, T. F. *et al.* Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. *Sci Immunol* **2**, doi:10.1126/sciimmunol.aan6809 (2017).
- 24 Setliff, I. *et al.* High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. *Cell*, doi:10.1016/j.cell.2019.11.003 (2019).
- 25 Chng, J. *et al.* Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells. *mAbs* **7**, 403-412, doi:10.1080/19420862.2015.1008351 (2015).
- 26 Crowe, J. E., Jr. Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design. *Cell host & microbe* **22**, 193-206, doi:10.1016/j.chom.2017.07.013 (2017).

- Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. *Nat Rev Immunol* 18, 46-61, doi:10.1038/nri.2017.106 (2018).
- Charretier, C. *et al.* Robust real-time cell analysis method for determining viral infectious titers during development of a viral vaccine production process. *J Virol Methods* 252, 57-64, doi:10.1016/j.jviromet.2017.11.002 (2018).
- 29 Tian, D. *et al.* Novel, real-time cell analysis for measuring viral cytopathogenesis and the efficacy of neutralizing antibodies to the 2009 influenza A (H1N1) virus. *PloS one* **7**, e31965, doi:10.1371/journal.pone.0031965 (2012).
- 30 Long, F. *et al.* Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope. *Proceedings of the National Academy of Sciences of the United States of America* **116**, 1591-1596, doi:10.1073/pnas.1815432116 (2019).
- 31 Zhao, H. *et al.* Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge. *J Exp Med* **217**, doi:10.1084/jem.20191792 (2020).
- 32 Erasmus, J. H. *et al.* A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika. *Mol Ther* **26**, 2507-2522, doi:10.1016/j.ymthe.2018.07.010 (2018).
- 33 Hong, M. *et al.* Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site. *J Virol* **87**, 12471-12480, doi:10.1128/JVI.01388-13 (2013).

- 34 Corti, D. *et al.* Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. *Proceedings of the National Academy of Sciences of the United States of America* **112**, 10473-10478, doi:10.1073/pnas.1510199112 (2015).
- Huang, J. *et al.* Isolation of human monoclonal antibodies from peripheral blood B cells.
 Nat Protoc 8, 1907-1915, doi:10.1038/nprot.2013.117 (2013).
- Guthmiller, J. J., Dugan, H. L., Neu, K. E., Lan, L. Y. & Wilson, P. C. An Efficient Method to Generate Monoclonal Antibodies from Human B Cells. *Methods in molecular biology* 1904, 109-145, doi:10.1007/978-1-4939-8958-4_5 (2019).
- 37 Esquivel, R. N. *et al.* In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus. *Mol Ther* **27**, 974-985, doi:10.1016/j.ymthe.2019.03.005 (2019).
- 38 Kose, N. *et al.* A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. *Sci Immunol* **4**, doi:10.1126/sciimmunol.aaw6647 (2019).
- 39 Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. *Mol Ther* **27**, 710-728, doi:10.1016/j.ymthe.2019.02.012 (2019).
- 40 Tsetsarkin, K. A. *et al.* A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development. *mBio* **7**, doi:10.1128/mBio.01114-16 (2016).


- 41 Abbink, P. *et al.* Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. *Science* **353**, 1129-1132, doi:10.1126/science.aah6157 (2016).
- 42 Larocca, R. A. *et al.* Vaccine protection against Zika virus from Brazil. *Nature* **536**, 474-478, doi:10.1038/nature18952 (2016).
- 43 Brien, J. D., Lazear, H. M. & Diamond, M. S. Propagation, quantification, detection, and storage of West Nile virus. *Curr Protoc Microbiol* **31**, 15D 13 11-15D 13 18, doi:10.1002/9780471729259.mc15d03s31 (2013).
- 44 Amanna, I. J., Raue, H. P. & Slifka, M. K. Development of a new hydrogen peroxide-based vaccine platform. *Nature medicine* **18**, 974-979, doi:10.1038/nm.2763 (2012).
- 45 Gilchuk, P. *et al.* Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization. *Immunity*, doi:10.1016/j.immuni.2020.01.001 (2020).
- 46 Soto, C. *et al.* High frequency of shared clonotypes in human B cell receptor repertoires. *Nature* **566**, 398-402, doi:10.1038/s41586-019-0934-8 (2019).
- 47 Giudicelli, V. & Lefranc, M. P. IMGT/junctionanalysis: IMGT standardized analysis of the V-J and V-D-J junctions of the rearranged immunoglobulins (IG) and T cell receptors (TR). *Cold Spring Harb Protoc* **2011**, 716-725, doi:10.1101/pdb.prot5634 (2011).
- 48 Davidson, E. & Doranz, B. J. A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. *Immunology* **143**, 13-20, doi:10.1111/imm.12323 (2014).
- 49 Govero, J. *et al.* Zika virus infection damages the testes in mice. *Nature* **540**, 438-442, doi:10.1038/nature20556 (2016).


50 Lazear, H. M. *et al.* A Mouse Model of Zika Virus Pathogenesis. *Cell host & microbe* **19**, 720-730, doi:10.1016/j.chom.2016.03.010 (2016).


Supernatant viral

Figure S1

a. ZIKV propagation in different cell lines by qRT-PCR (72 hrs)







c. ZIKV concentration and inactivation




Figure S2




Figure S3





Figure S4

a. Quality and purity of large-scale produced RNA



b. Human IgG concentration in mouse plasma after RNA delivery






Figure S5

a. NHP viremia



b. Human mAb concentration In NHP serum





Supplementary Figures

Supplementary Figure 1. ZIKV stock production.

(a) Propagation of ZIKV Dakar MA was assessed in a panel of immortalized cell lines. Viral growth was assessed by qRT-PCR from clarified cell culture supernatants harvested 72 hrs after virus inoculation. Data represented a single measurement from one experiment.

(b) Propagation of ZIKV Dakar MA in Vero cells grown in roller bottles was determined at various FBS concentrations. Viral growth was measured by FFA of culture supernatants. Data represented mean \pm SD values of technical duplicates from one experiment.

(**b**) Concentration and inactivation of ZIKV Dakar MA was assessed in indicated fractions obtained after ultra-centrifugation of infected Vero cell culture supernatant (72 hrs after virus inoculation), as well as following treatment with hydrogen peroxide. Viral titer was measured by FFA. LOD was 100 FFU/mL. Data represented a single measurement from one experiment.

Supplementary Figure 2. Frequency of ZIKV E-reactive memory B cells identified for previously infected subjects.

Percent (%) of ZIKV E-reactive B cells of total B cells was determined by flow cytometric analysis after staining of magnetically enriched B cells from each subject with phenotyping antibodies, biotinylated E protein, and fluorochrome-conjugated streptavidin as detailed in the *Methods* section. Subject with no history for ZIKV exposure served as a control for background E protein staining. Plots show measurements from individual subjects and represent viable CD19⁺IgM⁻IgD⁻ population of magnetically enriched B cells. Seven subjects selected for ZIKV-specific mAb discovery are indicated with "*" symbol.

Supplementary Figure 3. Rapid RTCA screening for neutralizing activity of mAbs to identify lead candidates for *in vivo* protection studies.

(a) Enlarged brightfield image (left) of shadowed electrodes and adherent Vero cells (with or without virus to visualize CPE) from single wells of 96-well E-plates (right).

(b) Representative sensorgrams for Vero cells that were inoculated with ZIKV (Brazil strain) in the presence of fully neutralizing ZIKV-117 (magenta) and partially neutralizing ZIKV-116 (green). mAbs ZIKV-117 and ZIKV-116 were described previously ⁵. Uninfected cells (blue) and infected cells without antibody addition (red) served as controls for intact monolayer and full CPE, respectively. Data represented mean \pm SD values of technical duplicates.

(c) Example sensorgrams from one 96-well E-plate analysis showing rapid identification of mAbs that fully neutralize ZIKV (indicated with grey arrows). Neutralization was assessed for 1:25 micro-scale purified mAbs dilution (see *Methods*) using ZIKV Brazil strain. Plates were measured continuously for 45 hrs after applying virus and mAb mixtures to the Vero cell monolayers.

Supplementary Figure 4. Large-scale production and qualification of ZIKV-753 and ZIKV-893 RNAs.

(a) Following large-scale *in vitro* transcription (IVT) and capping, ZIKV-752 and ZIKV-893 RNA were purified and concentrated by Capto Core chromatography and tangential flow filtration, prior to sterile-filtration and storage at -80°C. ZIKV-752 and -893 RNA were analyzed by denaturing gel electrophoresis as well as silver-stain SDS-PAGE to assess quality and purity of post-processed RNA.

To verify function, processed ZIKV-752 and -893 were formulated with NLC, and 40 μ g of formulation was injected intramuscularly into C57BL/6 mice (n=5/group). Blood was collected on days 3, 5, and 7,

and concentrations of total human IgG protein were determined in serum by ELISA using recombinant ZIKV-752 and -893 mAbs to generate a standard curve. Dots show measurements from individual mice and mean \pm SD values are shown.

Supplementary Figure 5. Efficacy of mAb treatment against ZIKV infection in NHPs.

Animals received one 10 mg/kg dose of mAb ZIKV-117 (n=3 NHPs) or mAb PGT121 (sham; n=3 NHPs) served as a contemporaneous control intravenously on day -1 and then challenged subcutaneously with a target dose of 10³ PFU of ZIKV strain Brazil the next day.

(a) qRT-PCR measurement of viremia in plasma and other compartments at indicated time points after virus challenge.

(b) Concentration of ZIKV-117 human mAb that was determined in serum of treated and control NHPs at indicated time points after virus challenge.

Supplementary Table 1. Research subject demographics and ZIKV exposure history

Subject ID	Gender	Age	Ethnicity	ZIKV strain lineage*	Year infected	Country in which infection occurred	PBMCs collection timepoint	
1001	Male	41	Hispanic or Latino	Asian	2015	Brazil	7 months after infection	
1011	Female	25	Not Hispanic or Latino	Asian	2016	Haiti	March 2016	
1046	Female	58	Hispanic or Latino	Asian	2016	Dominican Republic	>90 days after infection	
1054	Female	62	Not Hispanic or Latino	Asian	2016	Puerto Rico	>90 days after infection	
1057	Male	40	Not Hispanic or Latino	Asian	2016	Nicaragua	5 weeks and six months post 1st symptom	
1060	Female	35	Not Hispanic or Latino	Asian	2016	Guatemala	>90 days after infection	
1064	Male	19	Not Hispanic or Latino	Asian	2016	Guatemala	>90 days after infection	

* - The subjects likely had been infected with a strain of Asian lineage of ZIKV, since they contracted the disease during the recent outbreak in South America

Supplementary Table 3. Inferred antibody germline genes and variable region analysis of selected lead candidates that tested *in vivo* in mice

mAb		Heavy cha	ain varia	ble gene sequence	Light chain variable gene sequence						
clone	V-gene and allele	D-gene and allele	J-gene and allele	CDR3 amino acid sequence	V-gene and allele	J-gene and allele	CDR3 amino acid sequence				
ZIKV-423	3-23*01	3-10*01	4*02	AKDRTSGGFGELFKH	1-5*03	1*01	QHYHSYPWT				
ZIKV-434	3-48*03	3-3*01	4*02	ARDRYDFWSGDPMGYFDY	1-5*03	1*01	QQYNRGSWT				
ZIKV-518	5-10-1*01	3-22*01	2*01	ARATYSSSYDYWYFDV	3-21*02	3*02	QVWDDSSDQWV				
ZIKV-608	3-23*04	3-10*01	4*02	AKDRPSLGVGELYDY	1-5*03	J1*01	QQYNSYPWT				
ZIKV-609	3-23*01	6-19*01	4*02	AKDHPQWLGSHE	3-21*02	J1*01	QVWDSTRDQYV				
ZIKV-624	3-11*05	2-2*02	6*03	ARDRRLYTPYYHYYMDV	1-44*01	J3*02	AAWDDSLNGRV				
ZIKV-635	3-30*18	6-13*01	3*02	AKDSAGRRWQQLSAGI	2-28*01	J1*01	MQALQTPWT				
ZIKV-652	3-23*01	6-19*01	4*02	AKVIDQWLGFDY	3-21*02	J3*02	QVWDSSSDQWV				
ZIKV-668	3-49*05	3/15-3a*01	5*02	TRDFNDFWTGHHPNWFDP	1-39*01	1*01	QQSYSIPRT				
ZIKV-681	3-23*04	3-10*01	4*02	AKDRVVRGVGENLDH	1-27*01	1*01	QKYNSVPWT				
ZIKV-682	3-30*18	1-26*01	4*02	AKEREWEVRDGGFDY	3-21*02	2*01	QVWHSNTDHVV				
ZIKV-684	3-73*01	3-22*01	4*02	IRQGGYYESSEFDY	1-40*01	2*01	QSYDSSLTVHVV				
ZIKV-752	3-53*01	6-13*01	4*02	ARDRGYLDH	3-11*01	2*01	QQRSNWPYT				
ZIKV-869	3-13*01	2-2*01	6*02	ARVAHHSEYHLLYMPHGMDV	2-23*01	3*02	CSYTDNSPYVL				
ZIKV-893	3-23*04	3-16*02	3*02	ARDDEGYTTNWYDAYDI	1-39*01	3*01	QQNYNIPQVT				
ZIKV-922	3-23*04	3-10*01	4*02	AKDRPSRGVGELYDY	1-5*03	J1*01	QQYLSYPWT				
ZIKV-940	4-59*01	6-19*01	4*02	ARDCASGWDGCDF	1-44*01	1*01	AAWDDSLNGYV				
ZIKV-980	3-30*04	6-19*01	6*02	VRDRKVAGQMIRHGMDV	8-61*01	3*02	TLYMGSGISV				
ZIKV-1006	3-33*01	3-10*01	3*02	ARVGVRGADDAFDI	3-21*02	3*02	QVWDSNSDHGV				
ZIKV-1007	3-9*01	4-17*01	4*02	AKTKAYGDFHFDY	3-21*02	2*01	QLWDTSSNPHVV				

Supplementary Table 4. Efficacy of mAb-encoding RNA formulation and IgG protein treatment against ZIKV *in vivo* in mice

		IgG protein treatment, # survived/treated mice (% survival)													
mAb clone	Prophylatic RNA treatment, # survived/treated		Prophylaxi	s dose per mo	use, d-1		Treatmen mouse	•							
	mice (% survival)	70 µg	9 µg	4.5 μg	2 µg	1 µg	9 µg	4.5 μg							
ZIKV-423	2/5 (40%)	ND	ND	ND	ND	ND	ND	ND							
ZIKV-434	5/5 (100%)	1/5 (20%)	ND	ND	ND	ND	ND	ND							
ZIKV-518	0/5(0%)	ND	ND	ND	ND	ND	ND	ND							
ZIKV-608	0/5 (0%)	ND	ND	ND	ND	ND	ND	ND							
ZIKV-609	5/5 (100%)	ND	2/5 (40%)	ND	ND	ND	ND	ND							
ZIKV-624	5/5 (100%)	ND	3/5 (60%)	ND	ND	ND	ND	ND							
ZIKV-635	5/5 (100%)	5/5 (100%)	5/5 (100%)	ND	ND	ND	ND	ND							
ZIKV-652	5/5 (100%)	ND	ND	ND	ND	ND	ND	ND							
ZIKV-668	5/5 (100%)	4/5 (80%)	5/5 (100%)	ND	ND	ND	ND	ND							
ZIKV-681	2/5 (40%)	ND	ND	ND	ND	ND	ND	ND							
ZIKV-682	4/5 (80%)	ND	ND	ND	ND	ND	ND	ND							
ZIKV-684	5/5 (100%)	ND	ND	ND	ND	ND	ND	ND							
ZIKV-752	4/5 (80%)	5/5 (100%)	11/14 (79%)	7/9 (78%)	2/4 (50%)	2/4 (50%)	3/5 (60%)	3/5 (60%)							
ZIKV-869	2/5 (40%)	ND	4/5 (80%)	ND	ND	ND	ND	ND							
ZIKV-893	5/5 (100%)	5/5 (100%)	14/14 (100%)	4/4 (100%)	4/4 (100%)	0/4 (0%)	5/5 (100%)	4/5 (80%)							
ZIKV-922	0/5 (0%)	ND	ND	ND	ND	ND	ND	ND							
ZIKV-940	5/5 (100%)	ND	9/13 (69%)	3/4 (75%)	2/4 (50%)	2/4 (50%)	5/5 (100%)	4/5 (80%)							
ZIKV-980	1/5 (20%)	ND	0/5 (0%)	ND	ND	ND	ND	ND							
ZIKV-1006	0/5 (0%)	ND	1/5 (20%)	ND	ND	ND	ND	ND							
ZIKV-1007	0/5 (0%)	ND	ND	ND	ND	ND	ND	ND							
ZIKV-117 control	5/5 (100%)	ND	14/14 (100%)	9/9 (100%)	3/4 (75%)	0/4 (0%)	4/5 (80%)	5/5 (100%)							
FLU-5J8 control	1/5 (0%)	2/5 (40%)	0/5 (0%)	ND	ND	ND	1/5 (20%)	1/5 (20%)							
PBS control	1/5 (0%)	ND	ND	1/4 (25%)	1/4 (25%)	1/4 (25%)	ND	ND							

Supplementary Table 2. Characteristics of individual mAbs of the 598 recombinant mAbs panel

		Microscale purified sub-analysis to identify candidates for in vice study										Analysis of mid were used	Analysis of midiscale-purified mAb that were used for <i>in vivo</i> studies							
Cione ID	*Sorting method to isolate mAb		***ELISA binding O.D. 450 nm to ZIKV E2 assessed	***ELISA binding	*****Antigenic site	ZIKV Brazil neutralization	21KV Brazil	ZIKV Dakar	ZKV Brazil	ZIKV Dakar	21KV Brazil	ZIKV Dakar ICS0 (ng/mL) assessed	ZIKV Brazil ICS0	ZIKV Dakar ICS0	ZIKV Brazil ICS0	ADCP	*****ADNP	ADCD	ZIKV Dakar ICSC	ZIKV Brazil ICS0
	source map	**Purified mAb yield (µg)	***ELISA binding O.D. 450 nm to ZIKV 52 assessed for 1:10 OHO culture supernatant dilution	0.D.450 nm to ZIKV E2 assessed for 1:100 purified mAb dilution	****Antigenic site determined by competition binding with reference mAb	ZIKV Brazil neutralization assessed by RTCA for 1:10 OHO culture supernatant dilution (+/-)	neutralization assessed by RTCA for 1:25 purified mAb dilution (+/-)	2IKV Dakar neutralization assessed by FRNT for 1:16 purified mAb dilution (+/-)	neutralization assessed by FRNT for 1:16 purified mAb dilution (+/-)	ZIKV Dakar neutralization reassessed by RTCA for neutralizing mAbs	ZIKV Brazil neutralization reassessed by RTCA for neutralizing mAb	(ng/mL) assessed by RTCA for purified mAbs (ng/mL)	ZIKV Brazil ICS0 (ng/mL) assessed by RTCA for purified mAbs	ZIKV Dakar ICS0 (rg/mL) assessed by FIRNT for purified mAbs	(ng/mL) assessed by FRNT for purified mAbs	assessed for purified mAbs (relative units)	assessed for purified mAbs (relative units)	assessed for purified mAbs (relative units)	(ng/mL) assessed RTCA for purifier mAbs	ZIKV Brazil ICS0 by (ng/mL) assessed b RTCA for purified mAbs
2189-112 control 2189-023 2189-026	ND	222 21 41	3,4	4.2	50 50 50	+	*	•	+	+ 50 50	+ NO NO	42 10 10	7 50 50	34 %0	34 NO NO	34 22 54	8 4 5	287 15 15	ND ND ND	ND ND ND
2509-687 2509-688 2509-688 2509-688	92 92 92 92	4 -0.5 179 -66	-	-	10 10 10 10					50 50 50 50	ND ND ND		8 8 8	8 8 8	10 10 10 10	22 22 18 12	5 5 6 5	14 14 15 17	ND ND ND	ND ND ND
200-03 200-03 200-03 200-03 200-03	2 2 2 2	25 17 (8.5 24			10 10 10 10 10			•	+		NO NO NO NO	ND ND ND ND		8,582 ND ND ND	3,692 NO NO NO	24 56 21 22 18	5 5 6 6	12 12 16 15 17	ND ND ND ND ND	ND ND ND ND
200-037 200-038 200-039 200-033 200-031	N0 N0 N0 N0	93 25 40.5 40.5 150			50 50 50 50					50 50 50 50	ND ND ND ND	10 10 10 10	50 50 50 50	9 9 9 9	10 10 10 10	14 13 22 17	6 6 5 5	14 16 17 14	ND ND ND ND	ND ND ND ND
289-02 289-03 289-03 289-03	50 50 50 50	195 111 46 22	3.0	4.2	ND 118 ND ND	+	•	+ .	+	ND + ND ND	ND + ND ND	99 99 99 99	55 55 50	9 9 9	1,212 50 50	16 25 19 17	7 6 6	17 16 17 14	ND >3,000 ND ND	ND 305 ND ND
289-607 289-608 289-608 289-609 289-609	N2 N	40 (8.5 5 4 102			2 2 2 2					2 2 2 2	NO NO NO NO	2 20 20 20	2 2 2 2	2 9 9 9	20 30 30 30 30	21 25 55 13	2 6 5 5 5	10 12 13 15	ND ND ND ND	ND ND ND ND
200-403 200-402 200-403 200-404 200-404	Sub-panel 1 ND ND ND	45 45 5 92			50 50 50	•	•	•		50 50 +	ND ND +	ND ND 411	50 50 447	ND ND ND 730	NO NO 715	21 20 24 20	6 6 7 2	15 17 15 14	ND ND ND 112	ND ND 308
289-48 289-487 289-488 289-488	ND Sub-panel 2 ND Sub-panel 1	52 52 209 16 22	3.7	4.2	FL MD MD Unknown					10 10 10 10	N0 N0 N0 N0	10 10 10 10 10	2 2 2 2	2 2 2	ND ND ND ND	42 13 23 22	16 5 5 6	555 15 17 16	ND ND ND ND	ND ND ND ND
289-682 289-682 289-682 289-682 289-683	ND ND Sub-panel 1 ND	46 106 12 5 76			50 50 50 50					50 50 50 50	ND ND ND ND	10 10 10 10	10 10 10 10	9 9 9 9	ND ND ND ND	15 15 22 22 54	6 7 6 6	17 16 17 17 17	ND ND ND ND	ND ND ND ND
289-447 289-448 289-451 289-452	ND ND Sub-panel 2 ND	45 13 45 11			10 10 10				-	50 50 50 50	ND ND ND ND	9 9 9 9 9	2 2 2	9999	10 10 10 10	18 22 19 13	5 6 6	15 17 16	ND ND ND	ND ND ND
287-03 287-03 287-03 287-06 287-06	ND ND ND ND	48 (0.5 153 107 19			10 10 10 10 10 10	-	* 			- 10 10 10	+ NO NO NO	10 10 10 10	10 10 10 10 10	9 9 9 9	NO NO NO NO	22 20 12 14	6 6 7 5	16 17 19 20 15	ND ND ND ND	ND ND ND ND
289-08 289-09 289-00 289-00 289-00	ND ND Sub-panel 1 ND	9 41 45 43 43			2 2 2					2 2 2	ND ND ND ND	8 8 8 8 9 5	2 2 2 2	9 9 9 9 9 9	N0 N0 N0 N0	22 13 21 11	5 6 6	18 17 17 17	90 90 90 90 90	ND ND ND ND
289-663 289-665 289-665 289-667	ND Sub-panel 1 ND Sub-panel 1 Sub-panel 1	82 142 2 455		-	50 116 50 50					50 50 50 50	ND ND ND ND	10 10 10 10	20 20 20 20 20	- 9 9 9 9	NO NO NO NO	16 21 18	6 6 5	20 20 24 15 17	ND ND ND ND	ND ND ND
289-988 289-989 289-930 289-93 289-93	ND Sub-panel 2 Sub-panel 2 Sub-panel 1 ND	48.5 48.5 14 19 48.5	3.4	4.0	ND ND Unknown	-				50 50 50 50	ND ND ND ND ND	10 10 10 10 10	50 50 50 50 50	10 10 10 10	ND ND ND ND	20 19 18 20 19	6 6 6 6	17 16 18 18 19	ND ND ND ND ND	ND ND ND ND ND
289-43 289-43 289-43 289-43 289-43	ND ND Sub-panel 2	2.05 1 2.05 47		-	50 50 50 50 50					50 50 50 50	ND ND ND ND	10 ND ND ND	50 50 50 50 50	10 10 10 10	ND ND ND ND	16 14 21 14	5 5 5 6	20 17 16 16	ND ND ND ND	ND ND ND ND NO
284-87 284-88 284-89 284-80 284-80 284-80	Sub-panel 2 Sub-panel 1 Sub-panel 2 Sub-panel 2 Sub-panel 1 Sub-panel 1	88 -0.5 -67 -117 -84			10 10 10 10 10					20 20 20 20 20	ND ND ND ND	ND ND ND ND	8 8 8	2 9 9 9 9	NO NO NO NO	13 23 13 28 15	6 6 6 5	17 18 21 17 21	ND ND ND ND	+D ND ND ND ND
200-82 200-88 200-88 200-88 200-88 200-88	Sub-panel 1 ND ND Sub-panel 1 ND	11 9 59 21 2 ³			50 50 50 50					50 50 50 50	N0 N0 N0 N0	10 10 10 10	9999	ND ND ND ND	N0 N0 N0 N0 N0	17 21 12 18 22	5 5 6 6	17 19 19 19 19	ND ND ND ND ND	ND ND ND ND
289-487 289-488 289-489 289-481	ND Sub-panel 2 Sub-panel 1 ND	41.5 41.5 61 15			50 50 50					50 50 50	ND ND ND ND	2 2 2 2 2 2 2 2	29 29 29 29	9999	10 10 10 10	21 18 12 16	5 5 5	19 20 21 16	ND ND ND	ND ND ND
289-012 289-015 289-016 289-016 289-016	ND Sub-panel 2 ND Sub-panel 2 Sub-panel 1	<0.5 80 16 28 13			50 50 50 50 50					50 50 50 50	ND ND ND ND	ND 100 100 100	50 50 50 50	29 29 29 29 29 29	ND ND ND ND	14 17 14 12	5 5 5 4	19 18 25 20 20	ND ND ND ND	ND ND ND ND
282-007 2822-008 2822-009 2822-000 2822-000	Sub-panel 1 ND ND Sub-panel 1	109 17 8 98	0.4	0.8	136 ND ND ND		* 			- 30 30	- NO NO NO		888	6 6 6 6	ND ND ND ND	12 18 18 18	5	22 24 26 17	ND ND ND	ND ND ND
287-982 287-982 287-988 287-988 287-988	Sub-panel 2 Sub-panel 2 ND Sub-panel 2 ND	45 45 45 46			2 2 2 2					2 2 2 2	NO NO NO NO	2 20 20 20	2 2 2 2	2 9 9 9	20 30 30 30 30	18	5 5 5 5	19 19 19 19 19 21	ND ND ND ND	ND ND ND ND
289-106 289-107 289-108 289-108 289-109 289-100	ND ND Sub-panel 1 Sub-panel 1 Sub-panel 1	268 75 28 45	17	3.4	MD Unknown MD MD					20 20 20 20 20	ND ND ND ND	10 10 10 10 10	20 20 20 20 20 20 20 20 20 20 20 20 20 2	9 9 9 9 9	10 10 10 10	13 22 26 14 23	5 6 6 6	22 52 58 28 20 20	ND ND ND ND	ND ND ND ND
289-511 289-512 289-513 289-513	Sub-panel 1 Sub-panel 2 ND Sub-panel 2 Sub-panel 2	4 <0.5 20 150		-	20 20 20 20	+	•			- - 	NO 	999	999	9999	10 10 10 10	21 26 17 12	6 5 5	19 19 21 22	ND ND ND ND	ND ND ND
289-525 289-526 289-527 289-528 289-528 289-528	ND Sub-panel 1 Sub-panel 2 Sub-panel 1 ND	48 485 485 485 485		-	50 50 50 50 50					50 50 50 50 50	ND ND ND ND ND	ND ND ND ND ND	10 10 10 10 10	9 9 9 9	ND ND ND ND	15 22 22 24 24	5 6 6 6	22 18 19 17 18	ND ND ND ND ND	ND ND ND ND ND
289-521 289-525 289-526 289-526	Sub-panel 2 Sub-panel 2 Sub-panel 2 Sub-panel 1	120 c0.5 95 70	-	-	10 10 10 10		-			50 50 50	ND ND ND		8 8 8	6 6 6 6	ND ND ND ND	18 18 10	6 5 5 5	17 19 27 22	ND ND ND	ND ND ND
289-539 289-539 289-530 289-531 289-532	Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 2 Sub-panel 1	1 45 45			10 10 10 10 10					2 2 2 2 2 2 2 2	N0 N0 N0 N0 N0	2 20 20 20 20 20 20 20 20 20 20 20 20 20		2 2 2 2	N0 N0 N0 N0 N0	21 22 22 20	6 6 6	20 20 18 18 17	ND ND ND ND ND	ND ND ND ND
289-588 289-586 289-586 289-587 289-588	Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 2	84 88 42 7 45			50 50 50 50					50 50 50 50	N0 N0 N0 N0	10 10 10 10	10 10 10 10	9 9 9 9 9 9 9 9 9	N0 N0 N0 N0	11 15 23 22	5 5 6 6	21 25 20 18	ND ND ND ND	ND ND ND ND
289-540 289-540 289-541 289-543	Sub-panel 2 Sub-panel 2 Sub-panel 2 Sub-panel 1	2 72 94 92			50 50 50 50					50 50 50 50	ND NO NO		99 99 99 99 99 99 99 99 99 99 99 99 99	9 9 9 9	ND ND ND	23 54 55 55	6 6 6	17 18 17 16	ND ND ND	ND ND ND
289-545 289-545 289-546 289-547 289-548	Sub-panel 2 Sub-panel 2 ND Sub-panel 1 Sub-panel 1	96 30 35 87 13			10 10 10 10 10					10 10 10 10 10	ND ND ND ND ND	90 90 90 90	20 20 20 20 20 20	9 9 9 9	ND ND ND ND	3 20 13 13 21	6 6 7 6	22 20 18 18 19	ND ND ND ND	ND ND ND ND
289-549 289-500 289-501 289-502	ND Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 2	45 45 45 116			10 20 20 20 20 20 20 20 20 20 20 20 20 20					20 20 20 20 20 20 20 20 20 20 20 20 20 2	ND ND ND	5 6 6 6	5 6 6 6	5 6 6 6	10 20 20 20 20 20 20 20 20 20 20 20 20 20	20 23 15 11	6 6 5 5	18 19 21 27 27	ND ND ND	ND ND ND ND
289-334 289-335 289-336 289-336 289-337		2 5 220 166			50 50 50 50					50 50 50 50	N0 N0 N0 N0 N0	10 10 10 10 10	2 2 2 2 2	9 9 9 9 9	ND ND ND ND	21 20 24 25	6 6 7 8	19 21 16 18	ND ND ND ND	ND ND ND ND
282-558 282-559 282-560 282-561 282-561	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1	22 (0.5) 63 4 1			50 50 50 50 50					50 50 50 50	N0 N0 N0 N0 N0	10 10 10 10 10	50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 5	10 10 10 10	ND ND ND ND ND	12 16 15 18 19	5 5 6	20 22 24 26 26 26 26 26 26 26 26 26 26 26 26 26	ND ND ND ND	10 ND ND ND
200-568 200-566 200-566 200-567	Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 2 Sub-panel 1 ND Sub-panel 1	1 123 52 225 10 ⁴	4.0 1.8 3.6 3.6	3.9 2.4 4.1 4.0	FL Unknown MD DIII Unknown					9999	N0 N0 N0 N0	10 10 10 10	50 50 50 50 50	10 10 10 10 10	N0 N0 N0 N0	19 28 8 57	6 7 7 22	17 44 20 565	ND ND ND ND	ND ND ND ND
289-568 289-569 289-530 289-531 289-532 289-532	ND Sub-panel 1 ND Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 1	4	23	3.5	Unknown ND DIII ND	*	• • •	-	•	50 50 50	N0 + N0 N0	ND ND ND ND	50 574 50 50	10 10 10	NO 61 NO NO	12 18 20 12 12	10 5 5 6	22 22 22 23	ND ND ND ND	ND ND ND ND
289-535 289-535 289-536 289-537 289-537 289-539	ND Sub-panel 1 Sub-panel 1	21 205 -0.5 -0.5 -0.5 -5			50 50 50 50 50			-		50 50 50 50 50	ND ND ND ND ND	10 10 10 10	50 50 50 50 50	10 10 10 10	ND ND ND ND	20 56 55 55 13	6 8 5 5	19 22 22 22 22 29	ND ND ND ND	ND ND ND ND ND
2879-580 2879-583 2879-584 2879-585 2879-585	Sub-panel 2 ND Sub-panel 1 Sub-panel 2	110 2 1 40.5			Unknown No No	-		•	-	+ 10 10 10	+ N0 N0 N0	9 99 99 99 99 95	492 50 50 50	5.931 NO NO NO	3.368 NO NO NO	16 17 17 18	5	18 21 22 21	ND ND ND ND	ND ND ND
2014-586 2014-587 2014-588 2014-588 2014-588 2014-588	Sub-panel 1 ND Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 1	41 172 2 6 3			10 10 10 10 10					20 20 20 20 20	ND ND ND ND	ND ND ND ND	8 8 8	10 10 10 10 10	ND ND ND ND ND	13 11 15 56 14	6 5 4 4 5	22 22 22 22 22	ND ND ND ND	+D ND ND ND ND
289-588 289-585 289-587 289-589 289-589 289-60	Sub-panel 1 Sub-panel 1	4 45 45 45			10 10 10 10 10					10 10 10 10 10	ND ND ND ND	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 10 10 10 10	9 9 9 9 9	10 10 10 10 10	14 12 14 14	4 4 4 4	24 25 22 24	ND ND ND ND	ND ND ND ND NO
280-600 280-600 280-600 280-606 280-605	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	65 43 43 44 50 65	-	-				•			ND ND ND ND ND	10 10 10 10	50 50 50	2 2 2 2	ND ND ND ND	14 19 12 18	4 4 5 5	22 22 22 19	ND ND ND ND	ND ND ND ND
2107-606 2107-608 2107-630 2107-632		112 122 97 2 29	2.8	3.8	MD DIII MD MD MD	+	+	+	•	50 + 50 50	ND + ND ND ND	10 10 10 10	50 75 50 50 50	ND 2,165 ND ND ND	ND 5,661 ND ND ND	16 27 14 17	6 6 5 4	19 20 19 19	ND >3,000 ND ND ND	ND 118 ND ND ND
289-433 289-434 289-438 289-438 289-439	Sub-panel 1 Sub-panel 2 Sub-panel 2 Sub-panel 1 Sub-panel 1	18 23 52 26			10 10 10			-		50 50 50	ND ND ND	90 90 90 90	50 50 50	9 9 9 9	ND ND ND ND	19 19 19 14 21	5 5 6	21 21 20 20 20	NO NO NO NO	ND ND ND ND
2879-633 2879-633 2879-633 2879-633 2879-635	Sub-panel 2 Sub-panel 1	44 24 40.5 40 40.5	11		ND ND Unknown ND ND					2 2 2 2 2 2 2	ND ND ND ND	20 20 20 20 20 20 20 20 20 20 20 20 20 2	8 8 8	2 2 2 2	NO NO NO NO	15 11 18 10 22	6 5 4 4 5	18 17 16 24 21	10 10 10 10 10	+D ND ND ND ND
285/436 285/438 285/439 285/430 285/430	Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 ND	-0.5 -0.5 -12 -126 -7.4	3.3	35	50 50 50 50 116					9 9 9 9 9	N0 N0 N0 N0	10 10 10 10	10 10 10 10 10 10	ND ND ND ND	N0 N0 N0 N0	22 20 22 15 34	5 6 6 6	19 21 20 18 34	ND ND ND ND	ND ND ND ND
287-446 287-435 287-436 287-437 287-437 287-438	Sub-panel 2 Sub-panel 2 Sub-panel 2 Sub-panel 1	50 145 40.5 40.5 8	3.3 0.6	3.5 0.6	Unknown No No	* 	*	•	*		+ NO NO NO	ND 258 ND ND ND	127 50 50	80 333 90 90 90	NO 647 NO NO NO	29 30 18 30 21	5 4 5 5	24 17 22 20 20	90 90 92 92 92	ND 171 ND ND ND
289-489 289-440 289-441 289-442 289-443	Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 2 Sub-panel 2	28 <0.5 28 5		-	50 50 50 50		-			50 50 50 50	ND ND ND ND ND	10 10 10 10	50 50 50 50 50	9 9 9 9 9	ND ND ND ND	19 20 21 22 19	6 6 5 5	20 18 18 16 16	ND ND ND ND	ND ND ND ND
287-666 287-666 287-667 287-668	Sub-panel 2 Sub-panel 2 Sub-panel 1 Sub-panel 2 Sub-panel 2 Sub-panel 1	178 40 24 91	3.2	2.9	Unknown Mo Unknown	-				50 50 50 50	ND ND ND ND	10 10 10 10	50 50 50	ND ND ND ND	ND ND ND	24 54 22 31	4 5 5 6	68 18 20 16	ND ND ND	ND ND ND
282-449 282-450 282-451 282-455 282-455	Sub-panel 1 Sub-panel 1 Sub-panel 1	-0.5 105 114 59 11	28 32 33	2.2 4.0 4.1	DIII R R NO					50 50 50 50 50	ND ND ND ND ND	90 90 90 90 90 90	50 50 50 50	10 10 10 10	N0 N0 N0 N0 N0	21 59 58 11 15	6 26 25 5 4	18 685 656 19 20	ND ND ND ND ND	ND ND ND ND ND
200-403 200-407 200-408 200-409 200-461 200-462	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 1	118 89 87 26		0.6	10 10 10 10	*	*	*	*	-	+ N2 N2 N2	9 9 9 9 9 9 9 9 9	111 50 50 50 50 50	9 9 9 9 9 5	1,143 NO NO NO	23 12 14 19	6 5 6 6	19 20 19 21	ND ND ND ND	ND ND ND ND
289-662 289-668	Sub-panel 1 Sub-panel 1	79	1	1	ND ND			1		ND ND	ND ND	ND ND	50 50	ND ND	ND ND	24	6	20	ND ND	ND ND

			[Micro	scale-purified mAb ana	alysis to identify candida	ates for in vivo study								Analysis of mid were used	iscale-purified mAb that for in vivo studies
Clone ID	*Sorting method to isolate mAb	**Purified mAb γield (μg)	***ELISA binding O.D. 450 nm to 21KV E2 assessed for 1:10 CHO culture supernatant dilution	***ELISA binding O.D.450 nm to ZIKV E2 assessed for 1:100 purified mAb dilution	****Antigenic site determined by competition binding with reference mAb	21KV Brazil neutralization assessed by RTCA for 1:10 OHO culture supernatant dilution (+/-)	21KV Brazil neutralization assessed by RTCA for 1:25 purified mAb dilution (+/-)	2IKV Dakar neutralization assessed by FRNT for 1:16 purified mAb dilution (+/-)	ZKV Brazil neutralization assessed by FRNT for 1:16 purified mAb dilution (+/-)	ZIKV Dakar neutralization reassessed by RTCA for neutralizing mAbs	ZIKV Brazil neutralization reassessed by RTCA for neutralizing mAb	ZIKV Dakar ICS0 (ng/mL) assessed by RTCA for purified mAbs (ng/mL)	ZIKV Brazil ICSO (ng/mL) assessed (by RTCA for purified mAbs	ZIKV Dakar ICSO ng/mL) assessed by FIRNT for purified mAbs	IKV Brazil ICSO (ng/mL) assessed by FRNT for surified mAbs	ADCP assessed for purified mAbs (relative units)	*****ADNP assessed for purified mAbs (relative units)	*****ADCD assessed for purified mAbs (relative units)	ZIKV Dakar ICSC (ng/mL) assessed RTCA for purifier mAbs	21KV Brazil ICSO by (ng/mL) assessed by d RTCA for purified mAbs
2%Y+865 2%Y+865 2%Y+866	Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1	-0.5 200 213			50 50 50			-	-	50 50 50	ND ND ND	ND ND ND	50 50 50	ND ND ND	ND ND ND	16 18 16	5	19 18 19	ND ND ND	ND ND ND
250-467 250-468 250-469 250-470	Sub-panel 2 Sub-panel 1 Sub-panel 1	68.5 84 11 176	0.6	0.3	MD Unknown MD	•	•	•	•	50 + 50 50	N0 + N0	ND 158 ND ND	50 109 50 50	ND 262 ND ND	ND 272 ND ND	21 54 21 56	5 6 7	21 22 20 20	ND 128 ND ND	ND 195 ND ND
2809471 2809473 2809473 2809477 2809477	Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1	40.5 142 7 52 190	3.1 3.5 1.9	2.8 3.4 1.8	MD Dill Unknown MD 116	•				50 50 50 50 +	N0 N0 N0 +	10 10 10 10	50 50 50 1,300	10 10 10 10	NO NO NO 2,809	22 22 25 20 20	3 8 4 5 6	20 255 22 22 22 17	ND ND ND ND	ND ND ND ND ND
289-480 289-481 289-483 289-483	Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 2	75 128 3 21	32	3.5	50 118 50 50		•		•	ND + ND ND	ND + ND ND	ND ND ND ND	ND 184 ND ND	ND 1.891 ND ND	ND 1.114 ND ND	13 32 21 21	6 8 6 6	21 22 19 18	ND >3.000 ND ND	ND 420 ND ND
2007-685 2007-687 2007-689 2007-690	Sub-panel 2 Sub-panel 2 Sub-panel 1 Sub-panel 1	22 116 89 156			666					9 9 9 9	ND ND ND ND	50 50 50 50	50 50 50 50	10 10 10	NO NO NO	11 15 12	5	19 24 21	ND ND ND	50 50 50
200-00 200-00 200-00 200-00 200-00	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	11 20 4 114	10	0.7	2 22 23 20 20					2 20 20 20 20 20	ND ND ND ND	ND ND ND ND	2 20 20 20 20	ND ND ND	ND ND ND ND	15 18 15	5	20 21 20 20 20 21	ND ND ND ND	ND ND ND ND
2/07-697 2/07-698 2/07-699 2/07-700	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	64 21 116 116	1.6 3.6 3.4	1.4 3.5 3.2	MD MD DIII Unknown DII	*		*	•	50 - - 50	NO - NO	10 10 10	9 9 9	9 9 9 9 9	ND ND 1,421 ND	16 18 22 23	5 5 9	28 25 21 209	ND ND ND ND	ND ND ND ND
2009-701 2009-702 2009-704 2009-705	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	58 <0.5 44 15	3.4	3.2	DII NO NO			-		50 50 50 50	N0 N0 N0 N0	50 50 50 50	50 50 50	10 10 10	ND ND ND	25 57 8 15	75	60 22 19 21	ND ND ND	ND ND ND ND
250-705 250-707 250-708 250-708	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	110 108 127 174	3.6	3.9	8 R. 8 8				+	2 2 2	ND ND ND ND	2 2 2	20 20 20 20 20 20 20 20 20 20 20 20 20 2	10 10 10	ND ND ND	10 28 10 11	4 18 5 4	84 834 25 20	ND ND ND ND	ND N
280-714 280-714 280-715 280-716 280-717	Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	-45.5 110 151 43	18 33	1.8 4.2	Unknown FL					2 22 22 22 22	ND ND ND ND	10 10 10 10	2 52 52 52 52	10 10 10 10	N0 N0 N0 N0	14 15 11 14 14	4 4 20 5	24 24 25 757 22	ND ND ND ND	ND ND ND ND
2809-728 2809-729 2809-720 2809-720	ND Sub-panel 1 Sub-panel 1 Sub-panel 1	45 99 48.5 27	3.7	4.1	R. 50 50	*	• • • •	-	-	- 50 50	+ NO NO NO	ND ND ND ND	50 50 50	20 20 20 20 20	1,639 NO NO NO	49 21 29 21	18 6 6 6	512 2 19 28	ND ND ND ND	ND ND ND ND
2009-722 2009-728 2009-728 2009-728	Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1	127 18 1 4			20 20 20 20		*	*		- 50 50 50	- NO NO	ND ND ND	ND ND ND	ND ND ND	ND ND ND	14 16 21 19	6 5 5	21 21 21 21 20	ND ND ND	ND ND ND ND
2009-732 2009-738 2009-739 2009-730 2009-730	Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 1	105 53 45 105 ch c			2 20 20 20 20 20					10 10 10 10 10	ND ND ND ND ND	10 10 10 10	2 29 29 29 29	ND ND ND ND	NO NO NO NO	12 12 18 15 24	6 6 7 5	19 2 17 27 16	10 ND ND ND ND	ND ND ND ND ND
200-733 200-734 200-736 200-735 200-737	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 1	60.4 80 167 60.5 107			9 9 9 9					20 20 20 20 20	ND ND ND ND	ND ND ND	8 8 8 8	10 10 10 10	ND NO NO	12 13 19 14	5	18 24 18 19	ND ND ND ND	ND ND ND ND
200-788 200-788 200-941 200-942	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	21 015 11 82	2.6	1.0	50 138 50 50	•	•	•	•	50 + 50 50	N0 + N0 N0	10 10 10	50 50 50 50	1676 1676 18	NO 1.678 NO NO	19 20 18	6	2 16 26 19	ND ND ND	ND ND ND
2859-762 2859-762 2859-764 2859-766 2859-766	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	40 202 191 25 44	3.6	3.8	ND DIII ND FL	•	+	*	+		40 + NO NO NO	40 7 NO NO	16 50 50 50	15 ND ND	16 ND ND ND	11 40 18 54 50	5 9 6 7 12	19 27 21 19 2	ND 7 ND ND ND	ND 16 ND ND ND
2869733 2869733 2869732 2869732	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	2	3.7	2.7	50 50 10 50	<u>.</u>				50 50 50	ND ND ND ND	ND ND ND	10 10 10	ND ND ND ND	ND ND ND	19 21 20 19	6	16 25 18 18	ND ND ND	ND ND ND
2869-738 2869-735 2869-736 2869-736	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	52 24 245 245	0.4	0.5	MD Unknown MD	-	-	-	-	50 50 50 50	ND ND ND ND	ND ND ND ND	50 50 50 50	10 10 10 10	NG NG NG NG	15 21 21 29	5 6 6 7	22 20 16 2	ND ND ND	ND ND ND
286-778 286-779 286-780 286-781	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	-0.5 27 84 41			2 2 2 2					2 2 2	ND ND ND ND	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	ND ND ND ND	20 21 11 14	6 5 5	15 23 19 19	ND ND ND ND	ND ND ND ND
2007 782 2007 788 2007 788 2007 789 2007 789	Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	4 76 83 16	35	3.5	ND ND Unknown	-	•				N0 N0 N0	10 10 10	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	20 20 20 20	N0 N0 N0 N0	22 12 67 26	6 7 14	11 12 290 24	ND ND ND ND	ND ND
2009-782 2009-788 2009-786 2009-786	Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 1	78 189 122 218	3.8	4.0	50 RL 50 50				-	50 50 50 50	ND ND ND ND	10 10 10	9 9 9	999	ND ND ND	12 45 20 15	6 23 7 6	19 758 25 21	ND ND ND ND	ND ND ND ND
2002 786 2002 787 2002 788 2002 788	Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1	12 78 115 142	1.9	1.5	ND ND Unknown			-		50 50 50 50	ND ND ND ND	10 10 10	10 50 50 50	10 10 10	ND ND ND ND	19 52 18 25	6 7 8 9	18 2 16	ND ND ND	ND ND ND ND
2109-800 2009-805 2009-805 2009-805	Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 1	24 75 40.5 4			2 2 2 2			-		50 50 50 50	ND ND ND ND	ND ND ND	50 50 50	ND ND ND	ND ND ND ND	22 13 14 20	6	18 20 21 20 21	ND ND ND ND	ND ND ND
2507-825 2507-825 2507-825 2507-827 2507-820	Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 2	83 14 			2 2 2					50 50 50 50 50	ND ND ND ND	ND ND ND ND ND	2 2 2 2 2	ND ND ND ND ND	ND ND ND ND	54 54 25 51	6 6 7 5	21 22 18 27 20	ND ND ND ND	ND ND ND ND ND
200-011 200-013 200-013 200-013	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 1	142 19 22 10			50 50 50 50				-	50 50 50	ND ND ND	10 10 10 10	10 10 10	20 20 20 20	ND ND ND ND	24 15 24 18	6 5 5 6	20 21 20 19	ND ND ND ND	ND ND ND ND
200-034 200-037 200-038 200-039	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	115 10 79 12	3.6 3.5	3.8 3.0	Unknown No		*	*	-	+ 50 50	+ N0 N0 N0	ND ND ND	218 50 50	1,761 ND ND	513 NO NO NO	41 20 14 19	8 6 7 6	2 18 30 21	>3,000 ND ND	299 ND ND
21KV-821 21KV-822 21KV-828 21KV-828	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	2 200 25 4	3.7	4.0	50 50 8 50				-	50 50 50 50	ND ND ND ND	ND ND ND ND	10 10 10	10 10 10 10	ND NO NO NO	18 14 41 19	5 5 9 5	24 20 178 2	ND ND ND ND	ND ND ND ND
280-882 280-882 280-882 280-883	Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 2	14 12 12 14			6 6 6					2 2 2	ND ND ND	10 10 10	9 9 9 9	9 9 9 9	ND ND ND ND	12 54 12 15	18 18 18 18 18	19 22 21 22	ND ND ND	ND ND ND
2007-885 2007-885 2007-885 2007-885 2007-885	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	40.5 292 24 71	3.8	4.0	Unknown No No	•	•		-		ND + ND ND ND	10 10 10 10	2 2 2	10 10 10	NO NO NO NO	11 37 12 11	4 16 4 4	22 554 22 2 2 2 20	ND ND ND ND	ND ND ND ND
2002-000 2002-000 2002-001 2002-002	Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 2	57 -0.5 16 48	33	3.5	Unknown MD MD			-		50 50 50 50	ND ND ND ND	ND ND ND ND	50 50 50	ND ND ND ND	ND ND ND	15 17 12 17	5 4 4 5	52 22 21 17	ND ND ND ND	ND ND ND ND
200483 200483 200483 200483	Sub-panel 1 Sub-panel 1 Sub-panel 1	22 45 40 102	1.8 3.5	1.6 3.9	so Unknown FL					2 2 2 2	N0 N0 N0	92 92 92 92 92	8 8 8	9 9 9 9 9 9	ND ND ND	19 10 17 46	5 6 6 21	16 24 17 510	ND ND ND	50 50 50 50
280-887 280-888 280-889 280-889	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 1	47 26 177 84	3.8	4.1	2 2 2					2 2 2	N0 N0 N0 N0	10 10 10	20 20 20 20 20 20 20 20 20 20 20 20 20 2	2 2 2	ND ND ND ND	18 20 54 53	6 6 5 5	17 19 16 16	ND ND ND ND	ND ND ND ND
2009-862 2009-865 2009-865 2009-865	Sub-panel 1 Sub-panel 1 Sub-panel 2 Sub-panel 1	52 72 8 125			50 50 50 50			-		50 50 50 50	ND ND ND ND	ND ND ND ND	50 50 50	ND ND ND ND	ND ND ND	12 12 19 13	6 6 7	22 14 14	ND ND ND ND	ND ND ND ND
289-888 289-887 289-888 289-888 289-888	Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 1	41 28 224 72	-	0.0	ND ND ND Ulake serve	+	•		•	50 50 50 10	ND ND ND	ND ND ND 640	50 50 56 55	20 20 945	NO NO 343	11 19 13 13	655	15 16 18 18	ND ND 283	ND ND 215
200403 200403 200403 200403 200403 200404	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	18 64 61 97	20 32	0.9	Unknown Unknown 50 50 50	•	•	+	•	50 - 50 50 50	ND + ND ND ND	ND ND ND ND	50 50 50 50	10 10 10 10	40 NO NO NO	22 25 50 51 51 74	6 7 6 6	22 16 16 17	ND ND ND ND	ND ND ND ND ND
286485 286485 286487 286487	Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1	44 45 45 45 45			999					9 9 9 9	N0 N0 N0 N0	10 10 10 10	50 50 50 50	ND ND ND	ND ND ND	15 17 20 16	5	17 16 16 15	ND ND ND ND	ND ND ND ND
289-879 289-880 289-881 289-881 289-882	Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1	485 72 485 485			50 50 50 50					50 50 50	N0 N0 N0	ND ND ND	10 10 10	10 10 10	N0 N0 N0 N0	17 13 17 15	666	15 18 15 17	ND ND ND	ND ND ND
2004 883 2004 883 2004 885 2004 885 2004 887	Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 2	08.5 126 8 45 20	3.7	3.7	116 ND ND Unknown	•				50 50 50	ND ND ND ND	ND ND ND ND	50 50 50 50	10 10 10	40 NO NO NO	17 18 19 11 ,1	5 6 6	18 17 23 15	ND ND ND ND	ND ND ND ND ND
2004 888 2004 889 2004 880 2004 880 2004 881	Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 2	2 2 2 5 6 2 6 2 6	32 35	3.3 3.8	R. 50 50	•				9 9 9 9 9	N0 N0 N0 N0	50 50 50 50	50 50 50 50	10 10 10 10	ND ND ND	14 19 18 11 15		17 15 19 17	ND ND ND ND	ND ND ND ND
200482 200483 200483 200483 200483	Sub-panel 2 Sub-panel 2 Sub-panel 1 Sub-panel 2	- 415 - 416 - 415	0.8		Unknown	+	+	+	+	50 + 50 50	ND + ND ND	ND <183 ND ND	™ <174 ™	ND 113 ND ND	ND 124 ND ND	19 20 16 17	6	16 22 18 17	ND 33 ND ND	54 52
2004-895 2004-897 2004-899 2004-800 2004-805	Sub-panel 1 Sub-panel 2 Sub-panel 2	142 14 2 2 45	15	1.3	Dill 50 50 50 50					50 50 50 50	ND ND ND ND	ND ND ND ND	50 50 50 50	40 NO NO NO	40 NO NO NO	19 18 17 15	8 6 5 5	44 16 17 17	ND ND ND ND	ND ND ND ND
2XV-902 2XV-902 2XV-903 2XV-905 2XV-906	Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 2				9 9 9					50 50 50	N0 N0 N0 N0	10 20 30 30	2 2 2 2	10 10 10 10	ND ND ND	26 25 25 20	6	22 18 15 18	ND ND ND ND	ND ND ND ND
289-807 289-808 289-808 289-909 289-909	Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	47 63 10 7			50 50 50					50 50 50	ND ND ND ND	ND ND ND ND	50 50 50 50	ND ND ND ND	ND ND ND ND	11 9 15 20	6 5 6	16 17 18 15	ND ND ND	ND ND ND
200-933 200-932 200-933 200-934 200-934	Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	485 1 9 17			50 50 50 50 50					50 50 50 50	ND ND ND ND	ND ND ND ND	50 50 50 50	40 NO NO NO	40 NO NO NO	19 15 16 18	6 6 6	25 17 15 18	ND ND ND ND	ND ND ND ND
285-935 285-935 285-937 285-938 285-938	Sub-panel 1 Sub-panel 2 Sub-panel 2 Sub-panel 2 Sub-panel 2 Sub-panel 2	11 85 615 245			8 8 6 F					2 2 2 F	N0 N0 N0 N0 N0	20 20 20 20 20	- 9 9 9	ND ND ND ND	ND ND ND ND	17 11 14 20 18	a	14 18 17 18 23	ND ND ND ND	ND ND ND ND ND
289-933 289-931 289-932 289-933	Sub-panel 2 Sub-panel 2 Sub-panel 2 Sub-panel 2 Sub-panel 2 Sub-panel 2	4 4 7	21 32	2.5 3.7		+	+	*	+	50 + + 50	ND + + ND	ND ND ND ND	42 <205 502	10 10 10 10	NO NO 479 NO	16 56 16 18	6 6 6	15 14 17 15	ND >3,000 ND	ND 235 ND
200-535 200-332 control 200-455 200-455 200-445	Sub-panel 2 ND ND Sub-panel 2	11 116 2 53	15 4.0	2.7 3.9	0111 51 50 50 50	-	+ 9 9 9	•	-	+	+ + NO NO	ND 3 ND ND	587 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	2.729 53 ND ND	821 55 NO NO NO	54 4,862 3,697 3,402 5 x 3 **	5 3,325 310 257 7/7	16 249,184 6,038 6,748 6,748	ND ND ND ND	ND ND ND ND ND
2XV-646 2XV-649 2XV-680 2XV-686	ND ND ND	201 c0.5 27 c0.5			9 99 99		9 9 9	-		20 20 20 20 20	N0 N0 N0 N0	10 10 10 10	50 50 50 50	ND ND ND ND	ND ND ND	4,437 3,296 3,595 4,211	280 442 294 434	6,545 6,700 5,484 6,788	ND ND ND ND	ND ND ND ND
289-980 289-938 289-932 289-932 289-933	Sub-panel 2 Sub-panel 1 Sub-panel 2 Sub-panel 2	64 71 64 69	3.6 4.1	3.5 3.6	ND DIII ND ND	*	9.9.9	+ + -	*	- + ND	+ + ND +	ND ND ND	59 59 50	ND ND ND ND	ND 1.970 ND	5,858 4,246 3,464 5,783	582 1,129 434 1,921	5,364 8,245 6,596 13,671	ND ND ND ND	ND ND ND
289-538 289-585 289-562 289-585 289-585	Sub-panel 1 ND Sub-panel 1 ND Sub-panel 1	22 c0.5 21 c0.5			9 9 9 9 9 9 9 9		9 9 9 9 5			50 50 50 50	ND ND ND ND	50 50 50 5	50 50 50 5	19 19 19 19 19	ND ND ND ND	2,923 3,709 3,346 3,426 3,235	484 427 446 224	6,222 7,070 5,960 6,801 5,452	ND ND ND ND	ND ND ND
289-538 289-582 289-582 289-588 289-588	Sub-panel 2 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1 Sub-panel 1	20 78 45 26	35	3.1	9 9 9 9 9 9		2 2 2 2				ND ND ND ND	40 10 10 10	2 20 20 20 20	ND ND ND	ND ND ND ND ND	1,225 1,243 4,243 4,928 5,964	426	5,452 6,296 5,705 7,094 251,557	ND ND ND ND	ND ND ND ND
289-980 289-986 289-986	Sub-panel 1 Sub-panel 1 Sub-panel 1	43 40 51		0.8	2 50 50	-	2 20 20	-		30 30	N0 N0	ND ND		ND ND	ND ND	4,484 6,318	2,145 452 2,094	251,557 7,652 160,082	ND	ND ND

Clone ID r is	*Sortine	1		Microscule purified mile analysis to identify candidates for in vivo story													Analysis of midiscale-purified mAb that were used for in vivo studies			
	*Sorting method to isolate mAb	**Purified mAb yield (µg)	***ELISA binding O.D. 450 nm to ZIKV E2 assessed for 1:10 OHO culture supernatant dilution	***ELISA binding 0.D.450 nm to ZIKV E2 assessed for 1:100 purified mAb dilution	****Antigenic site determined by competition binding with reference mAb	20KV Brazil neutralization assessed by RTCA for 1:10 OHO culture supernatiant dilution (+/-)	ZIKV Brazil neutralization assessed by RTCA of for 1:25 purified mAb dilution (+/-)	ZIKV Dakar neutralization assessed by FRNT for 1:16 purified mAb dilution (+/-)	ZKV Brazil neutralization assessed by FRNT for 1:16 purified mAb dilution (+/-)	ZIKV Dakar neutralization reassessed by RTCA for neutralizing mAbs	ZIKV Brazil neutralization reassessed by RTCA for neutralizing mAbs	ZIKV Dakar ICS0 (ng/mL) assessed by RTCA for purified mAbs (ng/mL)	ZIKV Brazil IC50 (ng/mL) assessed by RTCA for purified mAbs	ZIKV Dakar ICSO (rg/mL) assessed by FRNT for purified mAbs	ZIKV Brazil ICSO (ng/mL) assessed by FRNT for purified mAbs	***** ADCP assessed for purified mAbs (relative units)	assessed for purified mAbs (relative units)	assessed for purified mAbs (relative units)	ZIKV Dakar ICS0 (ng/mL) assessed by RTCA for purified mAbs	21KV Brazil ICS0 (ng/mL) assessed by RTCA for purified mAbs
250-308	Sub-canel 2	52	dilution		10		ND 10			N0	10	10	10	10	N0	3130	288	10.348	ND	ND
2/02-607 2/02-609	Sub-panel 1 Sub-panel 2 Sub-panel 1	45 23 56	4.1 3.8	4.0 3.3	a a Di		ND ND ND		-	50 50 +	ND ND +	2 2 36	50 50 38	10 10 367	N0 N0 115	4,177 3,434 7,050	295 321 5,729	5,988 6,012 542,580	ND ND 204	ND ND 125
	Sub-panel 1 Sub-panel 2 Sub-panel 2	28 27 78		-	MD Unknown	-	ND ND ND			50 50 +	ND 10 +	ND ND 5	50 50 20	ND ND 127	466 2.669	8,165 4,916 5,936	2,474 456 1,686	269,758 7,449 49,053	ND ND 689	ND ND 190
289-427 289-411 289-412	Sub-panel 1 Sub-panel 2 Sub-panel 1	26 c0.5 89	3.5 4.0	2.5	50 50 50		80 90 90			9 -	*	ND ND ND	50 50	6 6 6	2.669 NO NO	5,627 5,019 270,2	2,020 401 1,214	225,420 6,577 8,425	ND ND ND	ND ND ND
289-483 289-485 289-482	Sub-panel 1 Sub-panel 1 Sub-panel 2	47 44 51	4.0	3.8 3.7 4.0	S S DI		9 9 9	•		50 50 +	ND ND +	9 9 9	50 50 71	ND ND 567	ND ND 156	3,242 6,427 7,541	200 6,411 4,804	5,823 483,548 450,102	ND ND 309	ND ND 192
2X7455 2X7455 2X7455	Sub-panel 1 Sub-panel 1 Sub-panel 2	57 0 28	3.9	4.0 3.4	50 50 50	•	ND ND ND	•	:	50 50 +	ND ND +	ND ND ND	50 50 26	ND ND ND	ND ND 204	5,900 4,289 5,681	5,444 464 1,424	515,689 4,614 10,365	ND ND ND	ND ND ND
287-472 287-475 287-475	Sub-panel 1 Sub-panel 1 Sub-panel 1	<0.5 22 42	4.0	4.1	50 50 50		ND ND ND	-	•	ND ND ND	ND ND ND	ND ND ND	ND ND	ND ND ND	ND ND ND	5,250 3,332 5,817	280 258 4,825	5,553 5,650 511,648	ND ND ND	ND ND ND
280-438 280-482 280-485	Sub-panel 1 Sub-panel 1 Sub-panel 1	17 12 52	3.9 4.0	3.6 3.7 3.9	Unknown Dill	+	90 90 90	*		*	*	178 59	221 215	2,071 602	839 1,399	6,925 7,413 6,350	1,149 2,522 2,059	55,916 255,722 15,515	ND 221 ND	ND 204 ND
289-488	Sub-panel 1 Sub-panel 1 Sub-panel 1	19	4.0 4.0 0.7	3.9 3.8 3.8 0.3	9 9 9		90 90 90			10 10 10	ND ND ND	2 2	2 2	9 9 9	ND ND ND	6,245 7,905 6,885	7,051 341 6,683	414,034 5,234 284,891	ND ND ND	ND ND ND
289-70 289-70 289-70	Sub-panel 1 Sub-panel 1 Sub-panel 2	26	4.0 0.7	3.8 0.3	9 9 9	ł	90 90 90	•	•	50 + 50	10 + N0	2 2	329 50	9 9 9	2,150 NO	4,382 4,382 3,587 4,284	6,964 714 425	\$70,145 7,129 5,766	ND ND ND	ND ND ND
289-782 289-785 289-780	Sub-panel 1 Sub-panel 1 Sub-panel 1	29 42			9 9 9		90 90 90	+		50 50 50	NO NO NO	90 90 90 90	10 10 10	9 9	ND ND ND	2,760 5,505	624 625 641	5,812 5,832 5,134	ND ND ND	ND ND ND
200-200	Sub-panel 1 Sub-panel 1 Sub-panel 2	22			2 2 2		10 10 10			50 50 50	N0 N0	2 10 10	10 30 30	2 2 2	ND ND	4,428 2,281 2,454	449 241	5,102 5,951	ND ND ND	ND ND
2507-767 2507-768 2507-768	Sub-panel 1 Sub-panel 1 Sub-panel 1	43 43 45			2 2 2		29 29 29			10 10 10	NG NG NG	2 2 2 5	2 2 2	2 2 2	20 20 20	5,881 2,880 4,484 4,347	240 375 254	5,511 6,527 6,099	ND ND	ND ND
2507-760 2507-761 2507-768 2507-768	Sub-panel 1 Sub-panel 1 Sub-panel 1	2.85 2.85 14			2 2 2		ND ND ND	•		2 2 2 2	NG NG NG	2 2 2 5	2 2 2	20 20 20 20	2 22 25	4,555 4,555 4,844 4,464	878 645 317 544	5,034 5,641 6,033	ND ND ND	ND ND
2507 736 2507 737 2507 738	Sub-panel 1 Sub-panel 1 Sub-panel 1	43 12 48.5			1999		100 100 100			2 2	ND ND ND	2 2 2		2 20 20	NO NO NO	4,464 3,954 4,077 4,362	291 292 263 449	+,044 5,794 5,617 7 197	ND ND	ND ND
289-700 289-70	Sub-panel 2 Sub-panel 1 Sub-panel 2 Sub-panel 2	20	-		50 50 50	-	10 10 10			50 50 50	ND ND ND	ND ND ND	50 50 50	- 9 9	N0 N0 N0	4,362 8,160 4,516 5,667	248 257 296 274	14,836 5,602 5,413	ND ND ND	ND ND ND
2502-768 2502-768 2502-766	Sub-panel 2 Sub-panel 1 Sub-panel 2 Sub-panel 1 Sub-panel 1	54 58 58 74	-	-	50 50 50	-	10 10 10			50 50 50	ND ND ND	ND ND ND	50 50 50	- 9 9	N0 N0 N0	5,667 5,658 4,786 3,696	462 342 268	5,541 5,651 5,651	ND ND ND	ND ND ND
2837 767 2859 768 2859 768	Sub-panel 1 Sub-panel 2 Sub-panel 2 Sub-panel 2	52 54 56			50 50 50		ND ND ND			MD MD MD	ND ND ND	ND ND ND	ND ND ND	ND ND ND	ND ND ND	4,845 2,166 2,984	251 609 372	6,079 5,998 6,263	ND ND ND	ND ND ND
	Sub-panel 2 Sub-panel 1 Sub-panel 1	20 28 56	4.1	3.9	9 9 9	-	ND ND ND	-	-	50 50 50	ND ND ND	N 10	50 50 50	20 20 20	ND ND ND	2,525 6,724 4,329	419 5,869 437	6,740 450,018 6,817	ND ND ND	ND ND ND
252-788	Sub-panel 1 Sub-panel 1 Sub-panel 1	76 48 32	4.1	3.4	9 9 9	-	10 10 10	-		50 50 50	ND ND ND	N N N	50 50 50	10 10 10	ND ND ND	5,351 4,584 5,898	6,153 1,642 809	405,365 41,547 6,239	ND ND ND	ND ND ND
2102-829	Sub-panel 1 Sub-panel 1 Sub-panel 1	76 99 85	2.0	1.9	9 9 9	-	10 10 10	-		50 50 50	ND ND ND	N N N	50 50 50	10 10 10	ND ND ND	4,359 2,667 5,540	2,676 426 2,445	298,085 7,952 259,087	ND ND ND	ND ND ND
252424	Sub-panel 1 Sub-panel 1 Sub-panel 2	52 11 50	-	-	9 9 9	-	10 10 10	-		50 50 50	ND ND ND	N N N	50 50 50	10 10 10	ND ND ND	4,269 4,836 3,261	441 275 407	7,019 5,920 5,991	ND ND ND	ND ND ND
	Sub-panel 1 Sub-panel 1 Sub-panel 1	22 16 68	0.6	0.7	9 9 9	-	10 10 10	-		50 50 50	ND ND ND	N N N	50 50 50	10 10 10	ND ND ND	8,173 2,887 2,124	3,175 447 427	222,492 4,887 5,930	ND ND ND	ND ND ND
200-888 200-888 200-888	Sub-panel 1 Sub-panel 1 Sub-panel 1	22 51 52	0.2	0.2	9 9 9	-	90 90 90		-	50 50 50	ND ND ND	2 2 2	10 10 10	6 6	ND NO NO	3,126 5,287 5,217	421 974 268	6,836 131,482 5,826	ND ND ND	ND ND ND
200-886 200-887 200-888	Sub-panel 1 Sub-panel 1 Sub-panel 2	25 48.5 58		-	50 50 50		ND ND ND	-		ND ND ND	ND ND ND	10 10 10	ND ND ND	ND ND ND	ND ND ND	2,990 4,438 4,792	408 255 428	5,040 4,958 4,679	ND ND ND	ND ND ND
280-828 280-827 280-828	Sub-panel k Sub-panel k Sub-panel k	44 21 45		-	50 50 50		ND ND ND	-		ND ND ND	ND ND ND	10 10 10	ND ND ND	ND ND ND	ND ND ND	2,949 2,991 4,431	477 492 447	5,780 6,572 5,584	ND ND ND	ND ND ND
200-011	Sub-panel 2 Sub-panel 2 Sub-panel 2	2 50 1		-	9 9 9		ND ND ND			ND ND ND	ND ND ND	N N	50 50 50	90 90 90	ND ND ND	6,554 4,550 4,728	451 527 592	5,910 4,908 9,521	ND ND ND	ND ND ND
289-884	Sub-panel 2 Sub-panel 2 Sub-panel 2	92 67 28	15	3.0	9 9 9	+	ND ND ND	* 	*	+ 50 50	+ N0 N0	20 NO 20	50 50	90 90 90	1,475 NO NO	4,232 2,996 3,210	960 869 826	5,882 6,576 5,814	ND ND ND	ND ND
282-88	Sub-panel à Sub-panel à Sub-panel à	21 42 24		-	9 9 9		90 90 90	-		50 NO NO	ND ND ND	2 2 2	50 50 50	90 90 90	ND ND	4,545 4,202	485 264 420	6,888 5,162 5,767	ND ND ND	ND ND ND
289-940	Sub-panel 2 Sub-panel 2 Sub-panel 2	20	2.9	1.4	Unknown	-	20		-	*	N0 +	N0 8	22	20 72	NO 81	4,114	489 710	5,884 5,884 107,478	ND 22	ND 52
289-942 289-943	Sub-panel 2 Sub-panel 2 Sub-panel 2 Sub-panel 2	45 29 29	3.9	3.8	2 2 2 5	1	5 8 5			10 10	NO 1	2 2 2 5	2 2 2	5 8 8	N0 N0	2,265 5,582 6,267	505 2,590 2,201	5,222 5,222 224,725 270,749	ND ND ND	ND ND ND
202-945	Sub-panel 2 Sub-panel 2 Sub-panel 2	1	4.0	3.5	9 9 9		ND ND ND	-	-	50 50 50	NO NO NO	20 20 20	ND ND ND	ND ND ND	ND ND ND	6,476 4,792 3,608	2,641 254 429	228,751 4,212 5.465	ND ND ND	ND ND ND
287-98	Sub-panel 2 Sub-panel 2 Sub-panel 2	1 56	-		9 9 9		ND ND ND		-	ND ND ND	ND NG ND	N N N	50 50	90 90 90	ND NO NO	4,304 2,621 3,008	240 255 424	5,214 5,534 5,276	ND ND ND	ND ND ND
2KV-81 2KV-82	Sub-panel 2 Sub-panel 2 Sub-panel 2	29 67 53	-	-	9 9 9	-	10 10 10	-		50 50 50	ND ND ND	N N N	50 50 50	10 10 10	ND ND ND	3,229 3,351 2,897	449 629 667	6,072 5,858 5,351	ND ND ND	ND ND ND
289-854 289-855	Sub-panel k Sub-panel k Sub-panel k	56 58 56			50 50 50	-	ND ND ND			50 50 50	ND ND ND	ND ND ND ND	50 50 50	8 8 8	ND ND ND	2,167 2,692 2,005	604 680 280	6,660 5,242 5,053	ND ND ND	ND ND ND
2KV-957 2KV-958	Sub-panel 2 Sub-panel 2 Sub-panel 2	82 53 13			50 50 50		10 10 10			ND ND	NO NO NO	ND ND ND	50 50	9 9 9	NO NO NO	2,252 2,622 2,314	246 412 449	5,831 5,497 5,661	ND ND ND	ND ND ND
289-941 289-942	Sub-panel k Sub-panel k Sub-panel k	1 44 63		-	50 50 50		ND ND ND			50 50	NO NO	10 10 10	50 50 50	2 2 2	ND ND	3,228 3,321 3,458	251 415 415	5,019 5,328 4,750	ND ND ND	ND ND ND
2KV-965 2KV-966	Sub-panel 2 Sub-panel 2 Sub-panel 2	49 62 4		-	50 50		ND ND			ND ND ND	ND ND ND	ND ND	50 50 50	ND ND ND	ND ND	2,052 2,128 4,078	462 647 642	5,541 5,290 6,114	ND ND ND	ND ND
2/02/989	Sub-panel 2 Sub-panel 2 Sub-panel 2	0 1 2			50 50 51		ND ND ND			ND ND ND	ND ND ND	ND ND ND	50 50	10 10 10	N0 N0 N0	2,985 2,456 2,904	458 418 257	5,041 5,719 5,196 4,910	ND ND ND	ND ND ND
250-873 250-873 250-874	suti-panel à Suti-panel à Suti-panel à	4 8 6			2 2 2 2		8 8 8			42 30 30	ND ND ND	9 9 9	9 9 9 5	5 5 5	10 NO NO NO	4,015 2,999 4,026 2,691	412 367 645	6,915 6,368 6,788 6,788	40 ND ND	40 ND ND
282-325 282-325 282-327 282-377	sub-panel k Sub-panel k Sub-panel 2 Sub-panel 2	48.5 5 1			2 8 8		ND ND ND			2 2 2	N0 N0 N0	2 2 2 5	2 8 8	20 20 20	2 2 2 2	2,685 2,685 2,504 2,168	284 284 284	6,571 5,681 6,865 5,272	ND ND ND	ND ND ND
280-179 280-179 280-180 280-181	Sub-panel 2 Sub-panel 2 Sub-panel 2 Sub-panel 2	-01.5 -05.5 -22 -	18	1.2	Unknown	-	ND ND ND	•	•		ND + ND	ND ND 17 ND	33 10	ND ND 51 ND	NO 50 NO	2,582 2,582 2,432 2,836	425 282 2,080 4 ³¹	*,272 5,509 14,305 4,436	ND ND 101 ND	ND ND 45 ND
280-882 280-883 280-985	Sub-panel 2 Sub-panel 2 Sub-panel 2	4 4 5	-		2 8 8	-	10 10			50 50 50	NO NO NO	1 2 2 5	20 20 20	10 10	NO NO NO	4,267	-44 431 234 244	5,159 6,772 c ****	ND ND ND	ND ND ND
282/985 282/985 282/987	Sub-panel k Sub-panel k Sub-panel k	2		-		-	29			50 50 50	ND ND ND	ND ND ND	9 9 9	9 9 9	N0 N0 N0	2,475 4,064 2,367	278 421 242	5,169 5,055 5,055	ND ND ND	ND ND ND
2KV-988 2KV-989 2KV-990	Sub-panel k Sub-panel k Sub-panel k	415 26 27	3.1	2.2		-	29			50 50 50	ND ND ND	ND ND ND	9 9 9	9 9 9	N0 N0 N0	4248	294 1,426 444	4,652 150,228 5,534	ND ND ND	ND ND ND
282-981 282-982 282-988	Sub-panel 2 Sub-panel 2 Sub-panel 2	69 21 26	23	0.9	50 50 50	-	9 9 9			ND ND ND	ND ND ND	10 10 10	9 9 9	. 9 9	ND ND ND	4,282 2,217 2,628	1,064 306 479	78,854 5,419 5,545	ND ND ND	ND ND ND
282-996 282-995 282-996	Sub-panel k Sub-panel k Sub-panel k	65 64 52	15	0.4	50 50		ND ND ND			ND ND ND	ND ND ND	2 2	50 50 50	90 90 90	ND ND ND	2,867 4,896 2,717	477 1,107 664	6,180 127,094 4,775	ND ND ND	ND ND ND
282-998	Sub-panel k Sub-panel k Sub-panel k	48 29 24		-	50 50		ND ND ND			ND ND ND	ND ND ND	2 2	50 50 50	90 90 90	ND ND ND	3,222 3,217 2,624	628 645 665	6,178 5,182 5,178	ND ND ND	ND ND ND
2107-3201	Sub-panel k Sub-panel k Sub-panel k	66 55 4	3.2	1.2	50 50	1	ND ND ND	*	•	9 + 9	*	2 2	50 97 50	90 90 90	ND 1,666	2,962 5,236 2,731	1,241 2,577 451	18,621 225,664 5,941	ND ND ND	ND ND ND
2107-3205	Sub-panel k Sub-panel k Sub-panel k	16 <0.5 <0.5			50 50 50		ND ND ND			ND ND ND	ND ND ND	ND ND ND	50 50 50	ND ND ND	ND ND ND	2,662 4,515 2,005	642 371 329	6,425 4,628 5,895	ND ND ND	ND ND ND
250-3007	Sub-panel 2 Sub-panel 2 Sub-panel 1	49 70 52	4.0 3.8	3.5 2.2	117 Unknown	+	10 10			+ + ND	+ + NO	42 382 10	75 202 50	334 1,820	284 534	5,406 4,919 2,208	4,259 2,121 <u>4</u> 27	324,612 238,251 6,029	128 1,100 NO	138 426 ND
	Sub-panel 1 Sub-panel 1 Sub-panel 1	1 26 83	4.0	3.6	9 9 9		10 10 10			50 50 50	ND NO NO	ND ND ND	50 50 50	9 9 9	N0 N0 N0	2,447 1,996 2,491	1,789 505 509	209,031 4,992 6,082	ND ND ND	ND ND ND
* mAbs were isolated b	ND by indicated B c			- panel 1 - labeling with n was 5 µg/mL, and the		panel 2 - labeling with	ND intact E2 followed by	- y detection with fusion	oop-specific mAb; labe	no ing and detection is the s	no ame as for Sub-panel 2	ND and sorting of high-al	ND Hinity population onl	νο γ. ND – not determ	no ined when cells w	2,126 vere pooled from d	ass ifferent sorting appro	2,821 paches for the analysis	1 10	80

 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 rison of the activity m